{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,13]],"date-time":"2026-11-13T01:35:34Z","timestamp":1794533734542,"version":"4.9.1"},"reference-count":375,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2021,4,1]],"date-time":"2021-04-01T00:00:00Z","timestamp":1617235200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,4,1]],"date-time":"2021-04-01T00:00:00Z","timestamp":1617235200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2021,4,1]],"date-time":"2021-04-01T00:00:00Z","timestamp":1617235200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2021,4,1]],"date-time":"2021-04-01T00:00:00Z","timestamp":1617235200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2021,4,1]],"date-time":"2021-04-01T00:00:00Z","timestamp":1617235200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2021,4,1]],"date-time":"2021-04-01T00:00:00Z","timestamp":1617235200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2021,4,1]],"date-time":"2021-04-01T00:00:00Z","timestamp":1617235200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Progress in Lipid Research"],"published-print":{"date-parts":[[2021,4]]},"DOI":"10.1016\/j.plipres.2021.101094","type":"journal-article","created":{"date-parts":[[2021,2,23]],"date-time":"2021-02-23T16:24:41Z","timestamp":1614097481000},"page":"101094","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":255,"special_numbering":"C","title":["Bile acids and their receptors in metabolic disorders"],"prefix":"10.1016","volume":"82","author":[{"given":"Stefano","family":"Fiorucci","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eleonora","family":"Distrutti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adriana","family":"Carino","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Angela","family":"Zampella","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michele","family":"Biagioli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.plipres.2021.101094_bb0005","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1007\/164_2019_238","article-title":"The pharmacology of bile acids and their receptors","volume":"256","author":"Fiorucci","year":"2019","journal-title":"Handb Exp Pharmacol"},{"key":"10.1016\/j.plipres.2021.101094_bb0010","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1016\/j.plipres.2009.11.001","article-title":"Bile acid-activated receptors in the treatment of dyslipidemia and related disorders","volume":"49","author":"Fiorucci","year":"2010","journal-title":"Prog Lipid Res"},{"key":"10.1016\/j.plipres.2021.101094_bb0015","doi-asserted-by":"crossref","first-page":"1191","DOI":"10.1002\/j.2040-4603.2013.tb00517.x","article-title":"Bile acid metabolism and signaling","volume":"3","author":"Chiang","year":"2013","journal-title":"Compr Physiol"},{"key":"10.1016\/j.plipres.2021.101094_bb0020","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1146\/annurev.biochem.72.121801.161712","article-title":"The enzymes, regulation, and genetics of bile acid synthesis","volume":"72","author":"Russell","year":"2003","journal-title":"Annu Rev Biochem"},{"key":"10.1016\/j.plipres.2021.101094_bb0025","doi-asserted-by":"crossref","first-page":"1955","DOI":"10.1194\/jlr.R900010-JLR200","article-title":"Bile acids: regulation of synthesis","volume":"50","author":"Chiang","year":"2009","journal-title":"J Lipid Res"},{"key":"10.1016\/j.plipres.2021.101094_bb0030","first-page":"2269","article-title":"Planar bile acids in health and disease","volume":"2017","author":"Shiffka","year":"1859","journal-title":"Biochim Biophys Acta Biomembr"},{"key":"10.1016\/j.plipres.2021.101094_bb0035","doi-asserted-by":"crossref","first-page":"1283","DOI":"10.3389\/fphar.2018.01283","article-title":"Bile acids and their derivatives as potential modifiers of drug release and pharmacokinetic profiles","volume":"9","author":"Pavlovi\u0107","year":"2018","journal-title":"Front Pharmacol"},{"key":"10.1016\/j.plipres.2021.101094_bb0040","doi-asserted-by":"crossref","first-page":"591","DOI":"10.1016\/j.tips.2012.08.004","article-title":"Marine sponge steroids as nuclear receptor ligands","volume":"33","author":"Fiorucci","year":"2012","journal-title":"Trends Pharmacol Sci"},{"key":"10.1016\/j.plipres.2021.101094_bb0045","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0030443","article-title":"Discovery that theonellasterol a marine sponge sterol is a highly selective FXR antagonist that protects against liver injury in cholestasis","volume":"7","author":"Renga","year":"2012","journal-title":"PLoS One"},{"key":"10.1016\/j.plipres.2021.101094_bb0050","doi-asserted-by":"crossref","first-page":"4541","DOI":"10.1007\/s00216-019-01890-3","article-title":"A review of analytical platforms for accurate bile acid measurement","volume":"411","author":"Dutta","year":"2019","journal-title":"Anal Bioanal Chem"},{"key":"10.1016\/j.plipres.2021.101094_bb0055","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1194\/jlr.R001941","article-title":"Bile acids: analysis in biological fluids and tissues","volume":"51","author":"Griffiths","year":"2010","journal-title":"J Lipid Res"},{"key":"10.1016\/j.plipres.2021.101094_bb0060","article-title":"Determination of bile acids from human gallbladder by (1) H-MRS-protocol optimization and estimation of reproducibility","author":"Vermathen","year":"2020","journal-title":"NMR Biomed"},{"key":"10.1016\/j.plipres.2021.101094_bb0065","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1038\/s41586-020-2047-9","article-title":"Global chemical effects of the microbiome include new bile-acid conjugations","volume":"579","author":"Quinn","year":"2020","journal-title":"Nature"},{"key":"10.1016\/j.plipres.2021.101094_bb0070","doi-asserted-by":"crossref","first-page":"671","DOI":"10.1016\/j.cld.2018.06.006","article-title":"Inborn errors of bile acid metabolism","volume":"22","author":"Heubi","year":"2018","journal-title":"Clin Liver Dis"},{"key":"10.1016\/j.plipres.2021.101094_bb0075","doi-asserted-by":"crossref","first-page":"358","DOI":"10.1111\/j.1872-034X.2011.00779.x","article-title":"Urinary bile acid sulfate levels in patients with primary biliary cirrhosis","volume":"41","author":"Miura","year":"2011","journal-title":"Hepatol Res"},{"key":"10.1016\/j.plipres.2021.101094_bb0080","doi-asserted-by":"crossref","first-page":"104234","DOI":"10.1016\/j.phrs.2019.04.018","article-title":"Drugs and hepatic transporters: A review","volume":"154","author":"Jetter","year":"2020","journal-title":"Pharmacol Res"},{"key":"10.1016\/j.plipres.2021.101094_bb0085","doi-asserted-by":"crossref","first-page":"702","DOI":"10.1016\/j.molmed.2015.09.001","article-title":"Bile acid-activated receptors, intestinal microbiota, and the treatment of metabolic disorders","volume":"21","author":"Fiorucci","year":"2015","journal-title":"Trends Mol Med"},{"key":"10.1016\/j.plipres.2021.101094_bb0090","doi-asserted-by":"crossref","first-page":"669","DOI":"10.4161\/19490976.2014.969986","article-title":"Bacterial bile salt hydrolase in host metabolism: potential for influencing gastrointestinal microbe-host crosstalk","volume":"5","author":"Joyce","year":"2014","journal-title":"Gut Microbes"},{"key":"10.1016\/j.plipres.2021.101094_bb0095","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1194\/jlr.R500013-JLR200","article-title":"Bile salt biotransformations by human intestinal bacteria","volume":"47","author":"Ridlon","year":"2006","journal-title":"J Lipid Res"},{"key":"10.1016\/j.plipres.2021.101094_bb0100","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1017\/S1466252316000153","article-title":"Bacterial bile salt hydrolase: an intestinal microbiome target for enhanced animal health","volume":"17","author":"Geng","year":"2016","journal-title":"Anim Health Res Rev"},{"key":"10.1016\/j.plipres.2021.101094_bb0105","doi-asserted-by":"crossref","first-page":"975","DOI":"10.1007\/s10529-013-1434-9","article-title":"Cloning and analysis of bile salt hydrolase genes from Lactobacillus plantarum CGMCC No. 8198","volume":"36","author":"Gu","year":"2014","journal-title":"Biotechnol Lett"},{"key":"10.1016\/j.plipres.2021.101094_bb0110","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1111\/jam.12027","article-title":"Molecular cloning, characterization and comparison of bile salt hydrolases from Lactobacillus johnsonii PF01","volume":"114","author":"Chae","year":"2013","journal-title":"J Appl Microbiol"},{"key":"10.1016\/j.plipres.2021.101094_bb0115","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1080\/19490976.2015.1127483","article-title":"Consequences of bile salt biotransformations by intestinal bacteria","volume":"7","author":"Ridlon","year":"2016","journal-title":"Gut Microbes"},{"key":"10.1016\/j.plipres.2021.101094_bb0120","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1038\/nature08821","article-title":"A human gut microbial gene catalogue established by metagenomic sequencing","volume":"464","author":"Qin","year":"2010","journal-title":"Nature"},{"key":"10.1016\/j.plipres.2021.101094_bb0125","doi-asserted-by":"crossref","first-page":"332","DOI":"10.1097\/MOG.0000000000000057","article-title":"Bile acids and the gut microbiome","volume":"30","author":"Ridlon","year":"2014","journal-title":"Curr Opin Gastroenterol"},{"key":"10.1016\/j.plipres.2021.101094_bb0130","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1038\/s41586-019-1785-z","article-title":"Bile acid metabolites control T","volume":"576","author":"Hang","year":"2019","journal-title":"Nature"},{"key":"10.1016\/j.plipres.2021.101094_bb0135","doi-asserted-by":"crossref","first-page":"410","DOI":"10.1038\/s41586-019-1865-0","article-title":"Microbial bile acid metabolites modulate gut ROR\u03b3","volume":"577","author":"Song","year":"2020","journal-title":"Nature"},{"key":"10.1016\/j.plipres.2021.101094_bb0140","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1016\/j.cmet.2013.01.003","article-title":"Gut microbiota regulates bile acid metabolism by reducing the levels of tauro-beta-muricholic acid, a naturally occurring FXR antagonist","volume":"17","author":"Sayin","year":"2013","journal-title":"Cell Metab"},{"key":"10.1016\/j.plipres.2021.101094_bb0145","doi-asserted-by":"crossref","first-page":"2384","DOI":"10.1038\/ncomms3384","article-title":"Microbiome remodelling leads to inhibition of intestinal farnesoid X receptor signalling and decreased obesity","volume":"4","author":"Li","year":"2013","journal-title":"Nat Commun"},{"key":"10.1016\/j.plipres.2021.101094_bb0150","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1016\/j.mam.2017.06.002","article-title":"Interactions between gut bacteria and bile in health and disease","volume":"56","author":"Long","year":"2017","journal-title":"Mol Asp Med"},{"key":"10.1016\/j.plipres.2021.101094_bb0155","doi-asserted-by":"crossref","first-page":"2130","DOI":"10.1194\/jlr.M071183","article-title":"Cyp2c70 is responsible for the species difference in bile acid metabolism between mice and humans","volume":"57","author":"Takahashi","year":"2016","journal-title":"J Lipid Res"},{"key":"10.1016\/j.plipres.2021.101094_bb0160","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1194\/jlr.RA119000243","article-title":"A human-like bile acid pool induced by deletion of hepatic","volume":"61","author":"de Boer","year":"2020","journal-title":"J Lipid Res"},{"key":"10.1016\/j.plipres.2021.101094_bb0165","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1194\/jlr.C120000621","article-title":"Is CYP2C70 the key to new mouse models to understand bile acids in humans?","volume":"61","author":"Guo","year":"2020","journal-title":"J Lipid Res"},{"key":"10.1016\/j.plipres.2021.101094_bb0170","doi-asserted-by":"crossref","first-page":"480","DOI":"10.1194\/jlr.RA119000307","article-title":"Of mice and men: murine bile acids explain species differences in the regulation of bile acid and cholesterol metabolism","volume":"61","author":"Straniero","year":"2020","journal-title":"J Lipid Res"},{"key":"10.1016\/j.plipres.2021.101094_bb0175","doi-asserted-by":"crossref","first-page":"613","DOI":"10.2337\/db16-0663","article-title":"An intestinal farnesoid x receptor-ceramide signaling axis modulates hepatic gluconeogenesis in mice","volume":"66","author":"Xie","year":"2017","journal-title":"Diabetes"},{"key":"10.1016\/j.plipres.2021.101094_bb0180","first-page":"24","article-title":"Gut microbiota and intestinal FXR mediate the clinical benefits of metformin","volume":"2018","author":"Sun","year":"1919","journal-title":"Nat Med"},{"key":"10.1016\/j.plipres.2021.101094_bb0185","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1016\/j.taap.2014.12.005","article-title":"Individual bile acids have differential effects on bile acid signaling in mice","volume":"283","author":"Song","year":"2015","journal-title":"Toxicol Appl Pharmacol"},{"key":"10.1016\/j.plipres.2021.101094_bb0190","doi-asserted-by":"crossref","first-page":"19008","DOI":"10.1038\/srep19008","article-title":"Insights on FXR selective modulation. Speculation on bile acid chemical space in the discovery of potent and selective agonists","volume":"6","author":"Sepe","year":"2016","journal-title":"Sci Rep"},{"key":"10.1016\/j.plipres.2021.101094_bb0195","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1016\/j.jcmgh.2020.02.005","article-title":"A physiology-based model of bile acid distribution and metabolism under healthy and pathologic conditions in human beings","volume":"10","author":"Voronova","year":"2020","journal-title":"Cell Mol Gastroenterol Hepatol"},{"key":"10.1016\/j.plipres.2021.101094_bb0200","doi-asserted-by":"crossref","first-page":"1085","DOI":"10.1194\/jlr.R054114","article-title":"Intestinal transport and metabolism of bile acids","volume":"56","author":"Dawson","year":"2015","journal-title":"J Lipid Res"},{"key":"10.1016\/j.plipres.2021.101094_bb0205","doi-asserted-by":"crossref","first-page":"1233","DOI":"10.1053\/j.gastro.2018.11.069","article-title":"Current practice in the diagnosis of bile acid diarrhea","volume":"156","author":"Vijayvargiya","year":"2019","journal-title":"Gastroenterology"},{"key":"10.1016\/j.plipres.2021.101094_bb0210","doi-asserted-by":"crossref","first-page":"2848","DOI":"10.1111\/bph.14705","article-title":"Ursodeoxycholic acid accelerates bile acid enterohepatic circulation","volume":"176","author":"Zhang","year":"2019","journal-title":"Br J Pharmacol"},{"key":"10.1016\/j.plipres.2021.101094_bb0215","doi-asserted-by":"crossref","first-page":"2340","DOI":"10.1194\/jlr.R900012-JLR200","article-title":"Bile acid transporters","volume":"50","author":"Dawson","year":"2009","journal-title":"J Lipid Res"},{"key":"10.1016\/j.plipres.2021.101094_bb0220","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.bcp.2018.12.018","article-title":"Developments in bile salt based therapies: a critical overview","volume":"161","author":"Donkers","year":"2019","journal-title":"Biochem Pharmacol"},{"key":"10.1016\/j.plipres.2021.101094_bb0225","first-page":"66","article-title":"Hepatic uptake of conjugated bile acids is mediated by both sodium taurocholate cotransporting polypeptide and organic anion transporting polypeptides and modulated by intestinal sensing of plasma bile acid levels in mice","volume":"2017","author":"Slijepcevic","year":"1631","journal-title":"Hepatology"},{"key":"10.1016\/j.plipres.2021.101094_bb0230","doi-asserted-by":"crossref","first-page":"G300","DOI":"10.1152\/ajpgi.00157.2017","article-title":"Determinants of postprandial plasma bile acid kinetics in human volunteers","volume":"313","author":"Fiamoncini","year":"2017","journal-title":"Am J Physiol Gastrointest Liver Physiol"},{"key":"10.1016\/j.plipres.2021.101094_bb0235","doi-asserted-by":"crossref","first-page":"618","DOI":"10.1080\/07420528.2020.1733590","article-title":"Circadian rhythms and bile acid homeostasis: a comprehensive review","volume":"37","author":"Yu","year":"2020","journal-title":"Chronobiol Int"},{"key":"10.1016\/j.plipres.2021.101094_bb0240","doi-asserted-by":"crossref","first-page":"1012","DOI":"10.1053\/j.gastro.2015.01.045","article-title":"Interactions between nuclear receptor SHP and FOXA1 maintain oscillatory homocysteine homeostasis in mice","volume":"148","author":"Tsuchiya","year":"2015","journal-title":"Gastroenterology"},{"key":"10.1016\/j.plipres.2021.101094_bb0245","doi-asserted-by":"crossref","first-page":"1445","DOI":"10.1053\/j.gastro.2005.09.009","article-title":"Bile acid synthesis in humans has a rapid diurnal variation that is asynchronous with cholesterol synthesis","volume":"129","author":"G\u00e4lman","year":"2005","journal-title":"Gastroenterology"},{"key":"10.1016\/j.plipres.2021.101094_bb0250","doi-asserted-by":"crossref","first-page":"580","DOI":"10.1111\/j.1365-2796.2011.02466.x","article-title":"Pronounced variation in bile acid synthesis in humans is related to gender, hypertriglyceridaemia and circulating levels of fibroblast growth factor 19","volume":"270","author":"G\u00e4lman","year":"2011","journal-title":"J Intern Med"},{"key":"10.1016\/j.plipres.2021.101094_bb0255","doi-asserted-by":"crossref","first-page":"664","DOI":"10.1016\/j.jcmgh.2015.08.003","article-title":"Short-term circadian disruption impairs bile acid and lipid homeostasis in mice","volume":"1","author":"Ferrell","year":"2015","journal-title":"Cell Mol Gastroenterol Hepatol"},{"key":"10.1016\/j.plipres.2021.101094_bb0260","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1016\/j.jcmgh.2016.10.002","article-title":"Targeting the enterohepatic bile acid signaling induces hepatic autophagy via a CYP7A1-AKT-mTOR axis in mice","volume":"3","author":"Wang","year":"2017","journal-title":"Cell Mol Gastroenterol Hepatol"},{"key":"10.1016\/j.plipres.2021.101094_bb0265","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1038\/s41580-019-0199-y","article-title":"mTOR at the nexus of nutrition, growth, ageing and disease","volume":"21","author":"Liu","year":"2020","journal-title":"Nat Rev Mol Cell Biol"},{"key":"10.1016\/j.plipres.2021.101094_bb0270","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1016\/j.cell.2018.09.048","article-title":"Biological functions of autophagy genes: a disease perspective","volume":"176","author":"Levine","year":"2019","journal-title":"Cell"},{"key":"10.1016\/j.plipres.2021.101094_bb0275","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1186\/s12964-020-0525-1","article-title":"FXR-mediated inhibition of autophagy contributes to FA-induced TG accumulation and accordingly reduces FA-induced lipotoxicity","volume":"18","author":"Wu","year":"2020","journal-title":"Cell Commun Signal"},{"key":"10.1016\/j.plipres.2021.101094_bb0280","doi-asserted-by":"crossref","first-page":"1122","DOI":"10.1016\/j.jhep.2020.01.014","article-title":"FXR-dependent rubicon induction impairs autophagy in models of human cholestasis","volume":"72","author":"Panzitt","year":"2020","journal-title":"J Hepatol"},{"key":"10.1016\/j.plipres.2021.101094_bb0285","doi-asserted-by":"crossref","first-page":"1755","DOI":"10.15252\/embj.201695500","article-title":"A postprandial FGF19-SHP-LSD1 regulatory axis mediates epigenetic repression of hepatic autophagy","volume":"36","author":"Byun","year":"2017","journal-title":"EMBO J"},{"key":"10.1016\/j.plipres.2021.101094_bb0290","doi-asserted-by":"crossref","first-page":"1193","DOI":"10.1172\/JCI88893","article-title":"Nutrient-sensing nuclear receptors PPAR\u03b1 and FXR control liver energy balance","volume":"127","author":"Preidis","year":"2017","journal-title":"J Clin Invest"},{"key":"10.1016\/j.plipres.2021.101094_bb0295","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1038\/nature13961","article-title":"Nutrient-sensing nuclear receptors coordinate autophagy","volume":"516","author":"Lee","year":"2014","journal-title":"Nature"},{"key":"10.1016\/j.plipres.2021.101094_bb0300","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1038\/nature13949","article-title":"Transcriptional regulation of autophagy by an FXR-CREB axis","volume":"516","author":"Seok","year":"2014","journal-title":"Nature"},{"key":"10.1016\/j.plipres.2021.101094_bb0305","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1016\/j.coph.2020.04.008","article-title":"Bile acid-activated receptors and the regulation of macrophages function in metabolic disorders","volume":"53","author":"Fiorucci","year":"2020","journal-title":"Curr Opin Pharmacol"},{"key":"10.1016\/j.plipres.2021.101094_bb0310","doi-asserted-by":"crossref","first-page":"623","DOI":"10.1080\/13543784.2020.1763302","article-title":"Bile acid modulators for the treatment of nonalcoholic steatohepatitis (NASH)","volume":"29","author":"Fiorucci","year":"2020","journal-title":"Expert Opin Investig Drugs"},{"key":"10.1016\/j.plipres.2021.101094_bb0315","first-page":"9","article-title":"Bile acids activated receptors regulate innate immunity","volume":"2018","author":"Fiorucci","year":"1853","journal-title":"Front Immunol"},{"key":"10.1016\/j.plipres.2021.101094_bb0320","doi-asserted-by":"crossref","first-page":"1365","DOI":"10.1126\/science.284.5418.1365","article-title":"Bile acids: natural ligands for an orphan nuclear receptor","volume":"284","author":"Parks","year":"1999","journal-title":"Science"},{"key":"10.1016\/j.plipres.2021.101094_bb0325","doi-asserted-by":"crossref","first-page":"1362","DOI":"10.1126\/science.284.5418.1362","article-title":"Identification of a nuclear receptor for bile acids","volume":"284","author":"Makishima","year":"1999","journal-title":"Science"},{"key":"10.1016\/j.plipres.2021.101094_bb0330","doi-asserted-by":"crossref","first-page":"543","DOI":"10.1016\/S1097-2765(00)80348-2","article-title":"Endogenous bile acids are ligands for the nuclear receptor FXR\/BAR","volume":"3","author":"Wang","year":"1999","journal-title":"Mol Cell"},{"key":"10.1016\/j.plipres.2021.101094_bb0335","doi-asserted-by":"crossref","first-page":"714","DOI":"10.1016\/S0006-291X(02)02550-0","article-title":"Identification of membrane-type receptor for bile acids (M-BAR)","volume":"298","author":"Maruyama","year":"2002","journal-title":"Biochem Biophys Res Commun"},{"key":"10.1016\/j.plipres.2021.101094_bb0340","doi-asserted-by":"crossref","first-page":"3369","DOI":"10.1073\/pnas.051551698","article-title":"The nuclear receptor PXR is a lithocholic acid sensor that protects against liver toxicity","volume":"98","author":"Staudinger","year":"2001","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.plipres.2021.101094_bb0345","doi-asserted-by":"crossref","first-page":"977","DOI":"10.1210\/mend.16.5.0828","article-title":"Pregnane X receptor (PXR), constitutive androstane receptor (CAR), and benzoate X receptor (BXR) define three pharmacologically distinct classes of nuclear receptors","volume":"16","author":"Moore","year":"2002","journal-title":"Mol Endocrinol"},{"key":"10.1016\/j.plipres.2021.101094_bb0350","doi-asserted-by":"crossref","first-page":"1313","DOI":"10.1126\/science.1070477","article-title":"Vitamin D receptor as an intestinal bile acid sensor","volume":"296","author":"Makishima","year":"2002","journal-title":"Science"},{"key":"10.1016\/j.plipres.2021.101094_bb0355","doi-asserted-by":"crossref","first-page":"1216","DOI":"10.1002\/hep.27592","article-title":"Conjugated bile acid-activated S1P receptor 2 is a key regulator of sphingosine kinase 2 and hepatic gene expression","volume":"61","author":"Nagahashi","year":"2015","journal-title":"Hepatology"},{"key":"10.1016\/j.plipres.2021.101094_bb0360","doi-asserted-by":"crossref","first-page":"43290","DOI":"10.1038\/srep43290","article-title":"Hyodeoxycholic acid derivatives as liver X receptor \u03b1 and G-protein-coupled bile acid receptor agonists","volume":"7","author":"De Marino","year":"2017","journal-title":"Sci Rep"},{"key":"10.1016\/j.plipres.2021.101094_bb0365","doi-asserted-by":"crossref","first-page":"10166","DOI":"10.1038\/ncomms10166","article-title":"Intestine-selective farnesoid X receptor inhibition improves obesity-related metabolic dysfunction","volume":"6","author":"Jiang","year":"2015","journal-title":"Nat Commun"},{"key":"10.1016\/j.plipres.2021.101094_bb0370","first-page":"1422","article-title":"Ursodeoxycholic acid is a GPBAR1 agonist and resets liver\/intestinal FXR signaling in a model of diet-induced dysbiosis and NASH","volume":"2019","author":"Carino","year":"1864","journal-title":"Biochim Biophys Acta Mol Cell Biol Lipids"},{"key":"10.1016\/j.plipres.2021.101094_bb0375","doi-asserted-by":"crossref","first-page":"1866","DOI":"10.1126\/science.294.5548.1866","article-title":"Nuclear receptors and lipid physiology: opening the X-files","volume":"294","author":"Chawla","year":"2001","journal-title":"Science"},{"key":"10.1016\/j.plipres.2021.101094_bb0380","doi-asserted-by":"crossref","first-page":"T1","DOI":"10.1530\/JME-13-0173","article-title":"Understanding nuclear receptor form and function using structural biology","volume":"51","author":"Rastinejad","year":"2013","journal-title":"J Mol Endocrinol"},{"key":"10.1016\/j.plipres.2021.101094_bb0385","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.mam.2014.12.003","article-title":"Retinoic acid receptors: from molecular mechanisms to cancer therapy","volume":"41","author":"di Masi","year":"2015","journal-title":"Mol Asp Med"},{"key":"10.1016\/j.plipres.2021.101094_bb0390","doi-asserted-by":"crossref","first-page":"1336","DOI":"10.1126\/science.272.5266.1336","article-title":"An orphan nuclear hormone receptor that lacks a DNA binding domain and heterodimerizes with other receptors","volume":"272","author":"Seol","year":"1996","journal-title":"Science"},{"key":"10.1016\/j.plipres.2021.101094_bb0395","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1016\/j.cmet.2005.09.001","article-title":"Fibroblast growth factor 15 functions as an enterohepatic signal to regulate bile acid homeostasis","volume":"2","author":"Inagaki","year":"2005","journal-title":"Cell Metab"},{"key":"10.1016\/j.plipres.2021.101094_bb0400","doi-asserted-by":"crossref","first-page":"3030","DOI":"10.1194\/jlr.M038323","article-title":"Mechanistic insights into isoform-dependent and species-specific regulation of bile salt export pump by farnesoid X receptor","volume":"54","author":"Song","year":"2013","journal-title":"J Lipid Res"},{"key":"10.1016\/j.plipres.2021.101094_bb0405","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1074\/jbc.M209505200","article-title":"Natural structural variants of the nuclear receptor farnesoid X receptor affect transcriptional activation","volume":"278","author":"Zhang","year":"2003","journal-title":"J Biol Chem"},{"key":"10.1016\/j.plipres.2021.101094_bb0410","doi-asserted-by":"crossref","first-page":"891","DOI":"10.1016\/j.molmet.2015.09.005","article-title":"Bioenergetic cues shift FXR splicing towards FXR\u03b12 to modulate hepatic lipolysis and fatty acid metabolism","volume":"4","author":"Correia","year":"2015","journal-title":"Mol Metab"},{"key":"10.1016\/j.plipres.2021.101094_bb0415","doi-asserted-by":"crossref","first-page":"926","DOI":"10.1016\/j.bcp.2013.07.022","article-title":"Differential activation of the human farnesoid X receptor depends on the pattern of expressed isoforms and the bile acid pool composition","volume":"86","author":"Vaquero","year":"2013","journal-title":"Biochem Pharmacol"},{"key":"10.1016\/j.plipres.2021.101094_bb0420","doi-asserted-by":"crossref","first-page":"298","DOI":"10.1016\/j.molmed.2007.06.001","article-title":"Targeting farnesoid X receptor for liver and metabolic disorders","volume":"13","author":"Fiorucci","year":"2007","journal-title":"Trends Mol Med"},{"key":"10.1016\/j.plipres.2021.101094_bb0425","doi-asserted-by":"crossref","DOI":"10.1053\/j.gastro.2020.07.036","article-title":"FXR isoforms control different metabolic functions in liver cells via binding to specific DNA motifs","author":"Ramos Pittol","year":"2020","journal-title":"Gastroenterology"},{"key":"10.1016\/j.plipres.2021.101094_bb0430","doi-asserted-by":"crossref","DOI":"10.3390\/nu11051132","article-title":"Transcriptome analysis of dual FXR and GPBAR1 agonism in rodent model of NASH reveals modulation of lipid droplets formation","volume":"11","author":"Carino","year":"2019","journal-title":"Nutrients"},{"key":"10.1016\/j.plipres.2021.101094_bb0435","doi-asserted-by":"crossref","first-page":"2971","DOI":"10.1021\/jm0002127","article-title":"Identification of a chemical tool for the orphan nuclear receptor FXR","volume":"43","author":"Maloney","year":"2000","journal-title":"J Med Chem"},{"key":"10.1016\/j.plipres.2021.101094_bb0440","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1007\/164_2019_232","article-title":"Nonsteroidal FXR ligands: current status and clinical applications","volume":"256","author":"Gege","year":"2019","journal-title":"Handb Exp Pharmacol"},{"key":"10.1016\/j.plipres.2021.101094_bb0445","doi-asserted-by":"crossref","first-page":"3746","DOI":"10.1016\/j.bmcl.2016.05.070","article-title":"Novel substituted isoxazole FXR agonists with cyclopropyl, hydroxycyclobutyl and hydroxyazetidinyl linkers: understanding and improving key determinants of pharmacological properties","volume":"26","author":"Kinzel","year":"2016","journal-title":"Bioorg Med Chem Lett"},{"key":"10.1016\/j.plipres.2021.101094_bb0450","doi-asserted-by":"crossref","first-page":"3569","DOI":"10.1021\/jm025529g","article-title":"6alpha-ethyl-chenodeoxycholic acid (6-ECDCA), a potent and selective FXR agonist endowed with anticholestatic activity","volume":"45","author":"Pellicciari","year":"2002","journal-title":"J Med Chem"},{"key":"10.1016\/j.plipres.2021.101094_bb0455","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1007\/164_2019_227","article-title":"Obeticholic acid: an update of its pharmacological activities in liver disorders","volume":"256","author":"Fiorucci","year":"2019","journal-title":"Handb Exp Pharmacol"},{"key":"10.1016\/j.plipres.2021.101094_bb0460","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1007\/164_2019_237","article-title":"Chemistry and pharmacology of GPBAR1 and FXR selective agonists, dual agonists, and antagonists","volume":"256","author":"De Marino","year":"2019","journal-title":"Handb Exp Pharmacol"},{"key":"10.1016\/j.plipres.2021.101094_bb0465","doi-asserted-by":"crossref","first-page":"885","DOI":"10.1517\/13543776.2015.1045413","article-title":"Farnesoid X receptor modulators (2011\u20132014): a patent review","volume":"25","author":"Sepe","year":"2015","journal-title":"Expert Opin Ther Pat"},{"key":"10.1016\/j.plipres.2021.101094_bb0470","doi-asserted-by":"crossref","first-page":"16813","DOI":"10.1074\/jbc.M400646200","article-title":"The role of alpha1-fetoprotein transcription factor\/LRH-1 in bile acid biosynthesis: a known nuclear receptor activator that can act as a suppressor of bile acid biosynthesis","volume":"279","author":"del Castillo-Olivares","year":"2004","journal-title":"J Biol Chem"},{"key":"10.1016\/j.plipres.2021.101094_bb0475","doi-asserted-by":"crossref","first-page":"517","DOI":"10.1016\/S1097-2765(00)00051-4","article-title":"A regulatory cascade of the nuclear receptors FXR, SHP-1, and LRH-1 represses bile acid biosynthesis","volume":"6","author":"Goodwin","year":"2000","journal-title":"Mol Cell"},{"key":"10.1016\/j.plipres.2021.101094_bb0480","doi-asserted-by":"crossref","first-page":"41690","DOI":"10.1074\/jbc.M105117200","article-title":"Transcriptional regulation of the human sterol 12alpha-hydroxylase gene (CYP8B1): roles of heaptocyte nuclear factor 4alpha in mediating bile acid repression","volume":"276","author":"Zhang","year":"2001","journal-title":"J Biol Chem"},{"key":"10.1016\/j.plipres.2021.101094_bb0485","doi-asserted-by":"crossref","first-page":"1034","DOI":"10.1002\/hep.25740","article-title":"Mechanism of tissue-specific farnesoid X receptor in suppressing the expression of genes in bile-acid synthesis in mice","volume":"56","author":"Kong","year":"2012","journal-title":"Hepatology"},{"key":"10.1016\/j.plipres.2021.101094_bb0490","doi-asserted-by":"crossref","first-page":"3741","DOI":"10.1172\/JCI94029","article-title":"RNA-binding protein ZFP36L1 maintains posttranscriptional regulation of bile acid metabolism","volume":"127","author":"Tarling","year":"2017","journal-title":"J Clin Invest"},{"key":"10.1016\/j.plipres.2021.101094_bb0495","doi-asserted-by":"crossref","first-page":"322","DOI":"10.1053\/j.gastro.2003.06.005","article-title":"Enterohepatic bile salt transporters in normal physiology and liver disease","volume":"126","author":"Kullak-Ublick","year":"2004","journal-title":"Gastroenterology"},{"key":"10.1016\/j.plipres.2021.101094_bb0500","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1016\/j.mam.2013.12.001","article-title":"Clinical application of transcriptional activators of bile salt transporters","volume":"37","author":"Baghdasaryan","year":"2014","journal-title":"Mol Asp Med"},{"key":"10.1016\/j.plipres.2021.101094_bb0505","doi-asserted-by":"crossref","first-page":"140","DOI":"10.1053\/gast.2001.25503","article-title":"The orphan nuclear receptor, shp, mediates bile acid-induced inhibition of the rat bile acid transporter, ntcp","volume":"121","author":"Denson","year":"2001","journal-title":"Gastroenterology"},{"key":"10.1016\/j.plipres.2021.101094_bb0510","first-page":"157","article-title":"Farnesoid X receptor suppresses constitutive androstane receptor activity at the multidrug resistance protein-4 promoter","volume":"2011","author":"Renga","year":"1809","journal-title":"Biochim Biophys Acta"},{"key":"10.1016\/j.plipres.2021.101094_bb0515","first-page":"158733","article-title":"Opposite effects of the FXR agonist obeticholic acid on Mafg and Nrf2 mediate the development of acute liver injury in rodent models of cholestasis","volume":"2020","author":"Carino","year":"1865","journal-title":"Biochim Biophys Acta Mol Cell Biol Lipids"},{"key":"10.1016\/j.plipres.2021.101094_bb0520","doi-asserted-by":"crossref","first-page":"G1124","DOI":"10.1152\/ajpgi.00539.2005","article-title":"Upregulation of a basolateral FXR-dependent bile acid efflux transporter OSTalpha-OSTbeta in cholestasis in humans and rodents","volume":"290","author":"Boyer","year":"2006","journal-title":"Am J Physiol Gastrointest Liver Physiol"},{"key":"10.1016\/j.plipres.2021.101094_bb0525","doi-asserted-by":"crossref","first-page":"731","DOI":"10.1016\/S0092-8674(00)00062-3","article-title":"Targeted disruption of the nuclear receptor FXR\/BAR impairs bile acid and lipid homeostasis","volume":"102","author":"Sinal","year":"2000","journal-title":"Cell"},{"key":"10.1016\/j.plipres.2021.101094_bb0530","doi-asserted-by":"crossref","first-page":"753","DOI":"10.2174\/138955711796355258","article-title":"Farnesoid X receptor agonist for the treatment of liver and metabolic disorders: focus on 6-ethyl-CDCA","volume":"11","author":"Fiorucci","year":"2011","journal-title":"Mini-Rev Med Chem"},{"key":"10.1016\/j.plipres.2021.101094_bb0535","doi-asserted-by":"crossref","first-page":"173616","DOI":"10.1016\/j.ejphar.2020.173616","article-title":"Systematic review and meta-analysis of randomized controlled trials on the effects of obeticholic acid on the blood lipid profile: Insights into liver disorders and liver cancer","volume":"889","author":"Guan","year":"2020","journal-title":"Eur J Pharmacol"},{"key":"10.1016\/j.plipres.2021.101094_bb0540","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1016\/j.phrs.2018.07.014","article-title":"Future trends in the treatment of non-alcoholic steatohepatitis","volume":"134","author":"Fiorucci","year":"2018","journal-title":"Pharmacol Res"},{"key":"10.1016\/j.plipres.2021.101094_bb0545","doi-asserted-by":"crossref","first-page":"1408","DOI":"10.1172\/JCI21025","article-title":"Bile acids lower triglyceride levels via a pathway involving FXR, SHP, and SREBP-1c","volume":"113","author":"Watanabe","year":"2004","journal-title":"J Clin Invest"},{"key":"10.1016\/j.plipres.2021.101094_bb0550","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1210\/me.2002-0120","article-title":"Bile acids induce the expression of the human peroxisome proliferator-activated receptor alpha gene via activation of the farnesoid X receptor","volume":"17","author":"Pineda Torra","year":"2003","journal-title":"Mol Endocrinol"},{"key":"10.1016\/j.plipres.2021.101094_bb0555","doi-asserted-by":"crossref","first-page":"544","DOI":"10.1016\/S0016-5085(03)00896-5","article-title":"Farnesoid X receptor agonists suppress hepatic apolipoprotein CIII expression","volume":"125","author":"Claudel","year":"2003","journal-title":"Gastroenterology"},{"key":"10.1016\/j.plipres.2021.101094_bb0560","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1042\/bj20021532","article-title":"Synergism between nuclear receptors bound to specific hormone response elements of the hepatic control region-1 and the proximal apolipoprotein C-II promoter mediate apolipoprotein C-II gene regulation by bile acids and retinoids","volume":"372","author":"Kardassis","year":"2003","journal-title":"Biochem J"},{"key":"10.1016\/j.plipres.2021.101094_bb0565","doi-asserted-by":"crossref","first-page":"2563","DOI":"10.1074\/jbc.M209525200","article-title":"The farnesoid X-receptor is an essential regulator of cholesterol homeostasis","volume":"278","author":"Lambert","year":"2003","journal-title":"J Biol Chem"},{"key":"10.1016\/j.plipres.2021.101094_bb0570","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1016\/S0022-2275(20)30180-2","article-title":"BAREing it all: the adoption of LXR and FXR and their roles in lipid homeostasis","volume":"43","author":"Edwards","year":"2002","journal-title":"J Lipid Res"},{"key":"10.1016\/j.plipres.2021.101094_bb0575","doi-asserted-by":"crossref","first-page":"18793","DOI":"10.1074\/jbc.M109927200","article-title":"Regulation of ATP-binding cassette sterol transporters ABCG5 and ABCG8 by the liver X receptors alpha and beta","volume":"277","author":"Repa","year":"2002","journal-title":"J Biol Chem"},{"key":"10.1016\/j.plipres.2021.101094_bb0580","doi-asserted-by":"crossref","first-page":"H272","DOI":"10.1152\/ajpheart.01075.2008","article-title":"Antiatherosclerotic effect of farnesoid X receptor","volume":"296","author":"Mencarelli","year":"2009","journal-title":"Am J Physiol Heart Circ Physiol"},{"key":"10.1016\/j.plipres.2021.101094_bb0585","first-page":"50","article-title":"Activation of PXR induces hypercholesterolemia in wild-type and accelerates atherosclerosis in apoE deficient mice","volume":"2009","author":"Zhou","year":"2004","journal-title":"J Lipid Res"},{"key":"10.1016\/j.plipres.2021.101094_bb0590","doi-asserted-by":"crossref","first-page":"E820","DOI":"10.1152\/ajpendo.90763.2008","article-title":"Involvement of the vitamin D receptor in energy metabolism: regulation of uncoupling proteins","volume":"296","author":"Wong","year":"2009","journal-title":"Am J Physiol Endocrinol Metab"},{"key":"10.1016\/j.plipres.2021.101094_bb0595","doi-asserted-by":"crossref","first-page":"2331","DOI":"10.1172\/JCI2961","article-title":"Activation of cholesterol synthesis in preference to fatty acid synthesis in liver and adipose tissue of transgenic mice overproducing sterol regulatory element-binding protein-2","volume":"101","author":"Horton","year":"1998","journal-title":"J Clin Invest"},{"key":"10.1016\/j.plipres.2021.101094_bb0600","doi-asserted-by":"crossref","first-page":"231","DOI":"10.2174\/1381612013398185","article-title":"The nuclear receptors FXR and LXRalpha: potential targets for the development of drugs affecting lipid metabolism and neoplastic diseases","volume":"7","author":"Niesor","year":"2001","journal-title":"Curr Pharm Des"},{"key":"10.1016\/j.plipres.2021.101094_bb0605","doi-asserted-by":"crossref","first-page":"1194","DOI":"10.1093\/carcin\/bgi291","article-title":"Farnesol and geraniol chemopreventive activities during the initial phases of hepatocarcinogenesis involve similar actions on cell proliferation and DNA damage, but distinct actions on apoptosis, plasma cholesterol and HMGCoA reductase","volume":"27","author":"Ong","year":"2006","journal-title":"Carcinogenesis"},{"key":"10.1016\/j.plipres.2021.101094_bb0610","doi-asserted-by":"crossref","first-page":"1359","DOI":"10.1210\/me.2007-0089","article-title":"Regulation of hepatic Insig-2 by the farnesoid X receptor","volume":"21","author":"Hubbert","year":"2007","journal-title":"Mol Endocrinol"},{"key":"10.1016\/j.plipres.2021.101094_bb0615","doi-asserted-by":"crossref","first-page":"949","DOI":"10.1016\/j.febslet.2008.02.038","article-title":"Activation of the farnesoid X receptor represses PCSK9 expression in human hepatocytes","volume":"582","author":"Langhi","year":"2008","journal-title":"FEBS Lett"},{"key":"10.1016\/j.plipres.2021.101094_bb0620","doi-asserted-by":"crossref","first-page":"20799","DOI":"10.1074\/jbc.C700095200","article-title":"Catalytic activity is not required for secreted PCSK9 to reduce low density lipoprotein receptors in HepG2 cells","volume":"282","author":"McNutt","year":"2007","journal-title":"J Biol Chem"},{"key":"10.1016\/j.plipres.2021.101094_bb0625","doi-asserted-by":"crossref","first-page":"18602","DOI":"10.1074\/jbc.M702027200","article-title":"Binding of proprotein convertase subtilisin\/kexin type 9 to epidermal growth factor-like repeat A of low density lipoprotein receptor decreases receptor recycling and increases degradation","volume":"282","author":"Zhang","year":"2007","journal-title":"J Biol Chem"},{"key":"10.1016\/j.plipres.2021.101094_bb0630","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1016\/j.tibs.2006.12.008","article-title":"Molecular biology of PCSK9: its role in LDL metabolism","volume":"32","author":"Horton","year":"2007","journal-title":"Trends Biochem Sci"},{"key":"10.1016\/j.plipres.2021.101094_bb0635","doi-asserted-by":"crossref","first-page":"1133","DOI":"10.1111\/liv.12456","article-title":"Protective effects of farnesoid X receptor (FXR) on hepatic lipid accumulation are mediated by hepatic FXR and independent of intestinal FGF15 signal","volume":"35","author":"Schmitt","year":"2015","journal-title":"Liver Int"},{"key":"10.1016\/j.plipres.2021.101094_bb0640","doi-asserted-by":"crossref","first-page":"588","DOI":"10.1038\/s42255-019-0074-3","article-title":"Metabolic messengers: fibroblast growth factor 15\/19","volume":"1","author":"Gadaleta","year":"2019","journal-title":"Nat Metab"},{"key":"10.1016\/j.plipres.2021.101094_bb0645","doi-asserted-by":"crossref","first-page":"25123","DOI":"10.1074\/jbc.M112.375907","article-title":"Activation of the farnesoid X receptor induces hepatic expression and secretion of fibroblast growth factor 21","volume":"287","author":"Cyphert","year":"2012","journal-title":"J Biol Chem"},{"key":"10.1016\/j.plipres.2021.101094_bb0650","doi-asserted-by":"crossref","first-page":"1400","DOI":"10.1210\/me.2015-1155","article-title":"Minireview: roles of fibroblast growth factors 19 and 21 in metabolic regulation and chronic diseases","volume":"29","author":"Zhang","year":"2015","journal-title":"Mol Endocrinol"},{"key":"10.1016\/j.plipres.2021.101094_bb0655","doi-asserted-by":"crossref","first-page":"468","DOI":"10.1210\/er.2017-00016","article-title":"Fibroblast growth factor 21-metabolic role in mice and men","volume":"38","author":"Staiger","year":"2017","journal-title":"Endocr Rev"},{"key":"10.1016\/j.plipres.2021.101094_bb0660","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1038\/nrendo.2016.206","article-title":"FGF21 and metabolic disease in 2016: a new frontier in FGF21 biology","volume":"13","author":"Potthoff","year":"2017","journal-title":"Nat Rev Endocrinol"},{"key":"10.1016\/j.plipres.2021.101094_bb0665","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1016\/j.semcdb.2015.09.021","article-title":"Metabolic fibroblast growth factors (FGFs): Mediators of energy homeostasis","volume":"53","author":"Markan","year":"2016","journal-title":"Semin Cell Dev Biol"},{"key":"10.1016\/j.plipres.2021.101094_bb0670","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1186\/s12967-016-0821-0","article-title":"Regulation of fibroblast growth factor 15\/19 and 21 on metabolism: in the fed or fasted state","volume":"14","author":"Guan","year":"2016","journal-title":"J Transl Med"},{"key":"10.1016\/j.plipres.2021.101094_bb0675","first-page":"193","article-title":"Fibroblast growth factor signaling in metabolic regulation","volume":"6","author":"Nies","year":"2015","journal-title":"Front Endocrinol"},{"key":"10.1016\/j.plipres.2021.101094_bb0680","first-page":"4750","article-title":"An engineered FGF21 variant, LY2405319, can prevent non-alcoholic steatohepatitis by enhancing hepatic mitochondrial function","volume":"8","author":"Lee","year":"2016","journal-title":"Am J Transl Res"},{"key":"10.1016\/j.plipres.2021.101094_bb0685","first-page":"1011","article-title":"Lack of fibroblast growth factor 21 accelerates metabolic liver injury characterized by steatohepatities in mice","volume":"6","author":"Liu","year":"2016","journal-title":"Am J Cancer Res"},{"key":"10.1016\/j.plipres.2021.101094_bb0690","doi-asserted-by":"crossref","first-page":"1073","DOI":"10.1053\/j.gastro.2014.07.044","article-title":"Fibroblast growth factor 21 limits lipotoxicity by promoting hepatic fatty acid activation in mice on methionine and choline-deficient diets","volume":"147","author":"Fisher","year":"2014","journal-title":"Gastroenterology"},{"key":"10.1016\/j.plipres.2021.101094_bb0695","first-page":"579","article-title":"Counter-regulatory role of bile acid activated receptors in immunity and inflammation","volume":"10","author":"Fiorucci","year":"2010","journal-title":"Curr Mol Med"},{"key":"10.1016\/j.plipres.2021.101094_bb0700","doi-asserted-by":"crossref","first-page":"G543","DOI":"10.1152\/ajpgi.90585.2008","article-title":"A synthetic farnesoid X receptor (FXR) agonist promotes cholesterol lowering in models of dyslipidemia","volume":"296","author":"Evans","year":"2009","journal-title":"Am J Physiol Gastrointest Liver Physiol"},{"key":"10.1016\/j.plipres.2021.101094_bb0705","doi-asserted-by":"crossref","first-page":"961","DOI":"10.1172\/JCI0214505","article-title":"Bile acid-activated nuclear receptor FXR suppresses apolipoprotein A-I transcription via a negative FXR response element","volume":"109","author":"Claudel","year":"2002","journal-title":"J Clin Invest"},{"key":"10.1016\/j.plipres.2021.101094_bb0710","doi-asserted-by":"crossref","first-page":"1147","DOI":"10.2174\/0929867324666170124151940","article-title":"Farnesoid-X receptor (FXR) as a promising pharmaceutical target in atherosclerosis","volume":"24","author":"Moris","year":"2017","journal-title":"Curr Med Chem"},{"key":"10.1016\/j.plipres.2021.101094_bb0715","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0108270","article-title":"Dual activation of the bile acid nuclear receptor FXR and G-protein-coupled receptor TGR5 protects mice against atherosclerosis","volume":"9","author":"Miyazaki-Anzai","year":"2014","journal-title":"PLoS One"},{"key":"10.1016\/j.plipres.2021.101094_bb0720","doi-asserted-by":"crossref","first-page":"556","DOI":"10.1124\/jpet.112.196519","article-title":"Synthetic farnesoid X receptor agonists induce high-density lipoprotein-mediated transhepatic cholesterol efflux in mice and monkeys and prevent atherosclerosis in cholesteryl ester transfer protein transgenic low-density lipoprotein receptor (\u2212\/\u2212) mice","volume":"343","author":"Hambruch","year":"2012","journal-title":"J Pharmacol Exp Ther"},{"key":"10.1016\/j.plipres.2021.101094_bb0725","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0013238","article-title":"The bile acid sensor FXR protects against dyslipidemia and aortic plaques development induced by the HIV protease inhibitor ritonavir in mice","volume":"5","author":"Mencarelli","year":"2010","journal-title":"PLoS One"},{"key":"10.1016\/j.plipres.2021.101094_bb0730","first-page":"1401","article-title":"Effects of FXR in foam-cell formation and atherosclerosis development","volume":"2006","author":"Guo","year":"1761","journal-title":"Biochim Biophys Acta"},{"key":"10.1016\/j.plipres.2021.101094_bb0735","doi-asserted-by":"crossref","first-page":"1264","DOI":"10.1056\/NEJMoa054013","article-title":"Sequence variations in PCSK9, low LDL, and protection against coronary heart disease","volume":"354","author":"Cohen","year":"2006","journal-title":"N Engl J Med"},{"key":"10.1016\/j.plipres.2021.101094_bb0740","doi-asserted-by":"crossref","first-page":"2595","DOI":"10.1194\/jlr.M500390-JLR200","article-title":"Loss of functional farnesoid X receptor increases atherosclerotic lesions in apolipoprotein E-deficient mice","volume":"46","author":"Hanniman","year":"2005","journal-title":"J Lipid Res"},{"key":"10.1016\/j.plipres.2021.101094_bb0745","doi-asserted-by":"crossref","first-page":"1519","DOI":"10.1161\/ATVBAHA.109.197897","article-title":"A role of the bile salt receptor FXR in atherosclerosis","volume":"30","author":"Hageman","year":"2010","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"10.1016\/j.plipres.2021.101094_bb0750","doi-asserted-by":"crossref","first-page":"2316","DOI":"10.1161\/01.ATV.0000235697.35431.05","article-title":"FXR deficiency causes reduced atherosclerosis in Ldlr\u2212\/\u2212 mice","volume":"26","author":"Zhang","year":"2006","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"10.1016\/j.plipres.2021.101094_bb0755","doi-asserted-by":"crossref","first-page":"3668","DOI":"10.1073\/pnas.0400046101","article-title":"Expression and activation of the farnesoid X receptor in the vasculature","volume":"101","author":"Bishop-Bailey","year":"2004","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.plipres.2021.101094_bb0760","doi-asserted-by":"crossref","first-page":"H114","DOI":"10.1152\/ajpheart.00087.2015","article-title":"Cystathionine \u03b3-lyase, a H2S-generating enzyme, is a GPBAR1-regulated gene and contributes to vasodilation caused by secondary bile acids","volume":"309","author":"Renga","year":"2015","journal-title":"Am J Physiol Heart Circ Physiol"},{"key":"10.1016\/j.plipres.2021.101094_bb0765","doi-asserted-by":"crossref","first-page":"H21","DOI":"10.1152\/ajpheart.00577.2016","article-title":"Decoding the vasoregulatory activities of bile acid-activated receptors in systemic and portal circulation: role of gaseous mediators","volume":"312","author":"Fiorucci","year":"2017","journal-title":"Am J Physiol Heart Circ Physiol"},{"key":"10.1016\/j.plipres.2021.101094_bb0770","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1093\/cvr\/cvm016","article-title":"FXR-mediated regulation of eNOS expression in vascular endothelial cells","volume":"77","author":"Li","year":"2008","journal-title":"Cardiovasc Res"},{"key":"10.1016\/j.plipres.2021.101094_bb0775","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1016\/j.jash.2015.04.006","article-title":"Farnesoid X receptor agonist CDCA reduces blood pressure and regulates vascular tone in spontaneously hypertensive rats","volume":"9","author":"Li","year":"2015","journal-title":"J Am Soc Hypertens"},{"key":"10.1016\/j.plipres.2021.101094_bb0780","doi-asserted-by":"crossref","DOI":"10.1152\/ajpgi.00308.2020","article-title":"Metabolic consequences of ileal interruption of the enterohepatic circulation of bile acids","author":"van de Peppel","year":"2020","journal-title":"Am J Physiol Gastrointest Liver Physiol"},{"key":"10.1016\/j.plipres.2021.101094_bb0785","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1152\/physrev.00010.2008","article-title":"Role of bile acids and bile acid receptors in metabolic regulation","volume":"89","author":"Lefebvre","year":"2009","journal-title":"Physiol Rev"},{"key":"10.1016\/j.plipres.2021.101094_bb0790","doi-asserted-by":"crossref","first-page":"967","DOI":"10.1053\/j.gastro.2007.06.019","article-title":"Direct intestinal cholesterol secretion contributes significantly to total fecal neutral sterol excretion in mice","volume":"133","author":"van der Velde","year":"2007","journal-title":"Gastroenterology"},{"key":"10.1016\/j.plipres.2021.101094_bb0795","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1007\/164_2019_233","article-title":"Potential of intestine-selective FXR modulation for treatment of metabolic disease","volume":"256","author":"van Zutphen","year":"2019","journal-title":"Handb Exp Pharmacol"},{"key":"10.1016\/j.plipres.2021.101094_bb0800","doi-asserted-by":"crossref","first-page":"1126","DOI":"10.1053\/j.gastro.2016.12.037","article-title":"Intestinal farnesoid X receptor controls transintestinal cholesterol excretion in mice","volume":"152","author":"de Boer","year":"2017","journal-title":"Gastroenterology"},{"key":"10.1016\/j.plipres.2021.101094_bb0805","doi-asserted-by":"crossref","first-page":"1052","DOI":"10.1053\/j.gastro.2018.11.061","article-title":"Small heterodimer partner and fibroblast growth factor 19 inhibit expression of NPC1L1 in mouse intestine and cholesterol absorption","volume":"156","author":"Kim","year":"2019","journal-title":"Gastroenterology"},{"key":"10.1016\/j.plipres.2021.101094_bb0810","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1007\/164_2019_235","article-title":"The enterokine fibroblast growth factor 15\/19 in bile acid metabolism","volume":"256","author":"Cariello","year":"2019","journal-title":"Handb Exp Pharmacol"},{"key":"10.1016\/j.plipres.2021.101094_bb0815","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1002\/hep.22627","article-title":"Bile acids activate fibroblast growth factor 19 signaling in human hepatocytes to inhibit cholesterol 7alpha-hydroxylase gene expression","volume":"49","author":"Song","year":"2009","journal-title":"Hepatology"},{"key":"10.1016\/j.plipres.2021.101094_bb0820","doi-asserted-by":"crossref","first-page":"1621","DOI":"10.1126\/science.1198363","article-title":"FGF19 as a postprandial, insulin-independent activator of hepatic protein and glycogen synthesis","volume":"331","author":"Kir","year":"2011","journal-title":"Science"},{"key":"10.1016\/j.plipres.2021.101094_bb0825","doi-asserted-by":"crossref","first-page":"585","DOI":"10.1016\/j.cmet.2012.04.002","article-title":"A ceramide-centric view of insulin resistance","volume":"15","author":"Chavez","year":"2012","journal-title":"Cell Metab"},{"key":"10.1016\/j.plipres.2021.101094_bb0830","doi-asserted-by":"crossref","first-page":"832","DOI":"10.1194\/jlr.M002782","article-title":"Glucose stimulates cholesterol 7alpha-hydroxylase gene transcription in human hepatocytes","volume":"51","author":"Li","year":"2010","journal-title":"J Lipid Res"},{"key":"10.1016\/j.plipres.2021.101094_bb0835","doi-asserted-by":"crossref","first-page":"845","DOI":"10.1053\/j.gastro.2016.08.057","article-title":"An intestinal microbiota-farnesoid X receptor axis modulates metabolic disease","volume":"151","author":"Gonzalez","year":"2016","journal-title":"Gastroenterology"},{"key":"10.1016\/j.plipres.2021.101094_bb0840","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1038\/nm.3760","article-title":"Intestinal FXR agonism promotes adipose tissue browning and reduces obesity and insulin resistance","volume":"21","author":"Fang","year":"2015","journal-title":"Nat Med"},{"key":"10.1016\/j.plipres.2021.101094_bb0845","doi-asserted-by":"crossref","first-page":"1102","DOI":"10.1172\/JCI25604","article-title":"Farnesoid X receptor is essential for normal glucose homeostasis","volume":"116","author":"Ma","year":"2006","journal-title":"J Clin Invest"},{"key":"10.1016\/j.plipres.2021.101094_bb0850","doi-asserted-by":"crossref","first-page":"11039","DOI":"10.1074\/jbc.M510258200","article-title":"The farnesoid X receptor modulates adiposity and peripheral insulin sensitivity in mice","volume":"281","author":"Cariou","year":"2006","journal-title":"J Biol Chem"},{"key":"10.1016\/j.plipres.2021.101094_bb0855","doi-asserted-by":"crossref","first-page":"1006","DOI":"10.1073\/pnas.0506982103","article-title":"Activation of the nuclear receptor FXR improves hyperglycemia and hyperlipidemia in diabetic mice","volume":"103","author":"Zhang","year":"2006","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.plipres.2021.101094_bb0860","doi-asserted-by":"crossref","first-page":"1861","DOI":"10.2337\/db11-0030","article-title":"Farnesoid X receptor deficiency improves glucose homeostasis in mouse models of obesity","volume":"60","author":"Prawitt","year":"2011","journal-title":"Diabetes"},{"key":"10.1016\/j.plipres.2021.101094_bb0865","doi-asserted-by":"crossref","first-page":"729","DOI":"10.1016\/j.cmet.2011.03.019","article-title":"FGF15\/19 regulates hepatic glucose metabolism by inhibiting the CREB-PGC-1\u03b1 pathway","volume":"13","author":"Potthoff","year":"2011","journal-title":"Cell Metab"},{"key":"10.1016\/j.plipres.2021.101094_bb0870","doi-asserted-by":"crossref","first-page":"2202","DOI":"10.1128\/MCB.01004-12","article-title":"Farnesoid X receptor inhibits the transcriptional activity of carbohydrate response element binding protein in human hepatocytes","volume":"33","author":"Caron","year":"2013","journal-title":"Mol Cell Biol"},{"key":"10.1016\/j.plipres.2021.101094_bb0875","doi-asserted-by":"crossref","first-page":"984","DOI":"10.1210\/en.2004-0965","article-title":"Regulation of carbohydrate metabolism by the farnesoid X receptor","volume":"146","author":"Stayrook","year":"2005","journal-title":"Endocrinology"},{"key":"10.1016\/j.plipres.2021.101094_bb0880","doi-asserted-by":"crossref","first-page":"37098","DOI":"10.1074\/jbc.M112.339887","article-title":"Orphan nuclear receptor small heterodimer partner negatively regulates growth hormone-mediated induction of hepatic gluconeogenesis through inhibition of signal transducer and activator of transcription 5 (STAT5) transactivation","volume":"287","author":"Kim","year":"2012","journal-title":"J Biol Chem"},{"key":"10.1016\/j.plipres.2021.101094_bb0885","doi-asserted-by":"crossref","first-page":"11055","DOI":"10.1074\/jbc.M117.784322","article-title":"Farnesoid X receptor induces Takeda G-protein receptor 5 cross-talk to regulate bile acid synthesis and hepatic metabolism","volume":"292","author":"Pathak","year":"2017","journal-title":"J Biol Chem"},{"key":"10.1016\/j.plipres.2021.101094_bb0890","doi-asserted-by":"crossref","first-page":"7629","DOI":"10.1038\/ncomms8629","article-title":"Farnesoid X receptor inhibits glucagon-like peptide-1 production by enteroendocrine L cells","volume":"6","author":"Trabelsi","year":"2015","journal-title":"Nat Commun"},{"key":"10.1016\/j.plipres.2021.101094_bb0895","doi-asserted-by":"crossref","first-page":"1479","DOI":"10.2337\/db11-0815","article-title":"Bile acids acutely stimulate insulin secretion of mouse \u03b2-cells via farnesoid X receptor activation and K(ATP) channel inhibition","volume":"61","author":"D\u00fcfer","year":"2012","journal-title":"Diabetes"},{"key":"10.1016\/j.plipres.2021.101094_bb0900","doi-asserted-by":"crossref","first-page":"6626","DOI":"10.1074\/jbc.M115.699504","article-title":"Activation of transmembrane bile acid receptor TGR5 modulates pancreatic islet \u03b1 cells to promote glucose homeostasis","volume":"291","author":"Kumar","year":"2016","journal-title":"J Biol Chem"},{"key":"10.1016\/j.plipres.2021.101094_bb0905","first-page":"363","article-title":"The bile acid sensor FXR regulates insulin transcription and secretion","volume":"2010","author":"Renga","year":"1802","journal-title":"Biochim Biophys Acta"},{"key":"10.1016\/j.plipres.2021.101094_bb0910","doi-asserted-by":"crossref","first-page":"1263","DOI":"10.1210\/en.2014-1751","article-title":"Role of FXR in \u03b2-cells of lean and obese mice","volume":"156","author":"Schittenhelm","year":"2015","journal-title":"Endocrinology"},{"key":"10.1016\/j.plipres.2021.101094_bb0915","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1016\/j.cmet.2009.08.001","article-title":"TGR5-mediated bile acid sensing controls glucose homeostasis","volume":"10","author":"Thomas","year":"2009","journal-title":"Cell Metab"},{"key":"10.1016\/j.plipres.2021.101094_bb0920","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1007\/978-1-59745-157-4_4","article-title":"LC3 and autophagy","volume":"445","author":"Tanida","year":"2008","journal-title":"Methods Mol Biol"},{"key":"10.1016\/j.plipres.2021.101094_bb0925","doi-asserted-by":"crossref","first-page":"609","DOI":"10.1042\/EBC20170035","article-title":"Regulation of selective autophagy: the p62\/SQSTM1 paradigm","volume":"61","author":"Lamark","year":"2017","journal-title":"Essays Biochem"},{"key":"10.1016\/j.plipres.2021.101094_bb0930","doi-asserted-by":"crossref","first-page":"440","DOI":"10.1038\/s41467-020-14343-8","article-title":"Structural basis of p62\/SQSTM1 helical filaments and their role in cellular cargo uptake","volume":"11","author":"Jakobi","year":"2020","journal-title":"Nat Commun"},{"key":"10.1016\/j.plipres.2021.101094_bb0935","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1016\/j.ymeth.2014.11.021","article-title":"LC3- and p62-based biochemical methods for the analysis of autophagy progression in mammalian cells","volume":"75","author":"Jiang","year":"2015","journal-title":"Methods"},{"key":"10.1016\/j.plipres.2021.101094_bb0940","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1002\/mus.26608","article-title":"Autophagy markers LC3 and p62 accumulate in immune-mediated necrotizing myopathy","volume":"60","author":"Girolamo","year":"2019","journal-title":"Muscle Nerve"},{"key":"10.1016\/j.plipres.2021.101094_bb0945","doi-asserted-by":"crossref","first-page":"193","DOI":"10.6065\/apem.2016.21.4.193","article-title":"Transcriptional coordination of hepatic autophagy by nutrient-sensing nuclear receptor PPAR\u03b1 and FXR","volume":"21","author":"Lee","year":"2016","journal-title":"Ann Pediatr Endocrinol Metab"},{"key":"10.1016\/j.plipres.2021.101094_bb0950","doi-asserted-by":"crossref","DOI":"10.1096\/fj.202001386R","article-title":"The bile acid activated receptors GPBAR1 and FXR exert antagonistic effects on autophagy","volume":"35","author":"Carino","year":"2021","journal-title":"FASEB J"},{"key":"10.1016\/j.plipres.2021.101094_bb0955","doi-asserted-by":"crossref","first-page":"6251","DOI":"10.4049\/jimmunol.0803978","article-title":"The bile acid receptor FXR is a modulator of intestinal innate immunity","volume":"183","author":"Vavassori","year":"2009","journal-title":"J Immunol"},{"key":"10.1016\/j.plipres.2021.101094_bb0960","doi-asserted-by":"crossref","first-page":"6657","DOI":"10.4049\/jimmunol.0901347","article-title":"The bile acid sensor farnesoid X receptor is a modulator of liver immunity in a rodent model of acute hepatitis","volume":"183","author":"Mencarelli","year":"2009","journal-title":"J Immunol"},{"key":"10.1016\/j.plipres.2021.101094_bb0965","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1677\/joe.1.06546","article-title":"Targeted disruption of G protein-coupled bile acid receptor 1 (Gpbar1\/M-Bar) in mice","volume":"191","author":"Maruyama","year":"2006","journal-title":"J Endocrinol"},{"key":"10.1016\/j.plipres.2021.101094_bb0970","doi-asserted-by":"crossref","first-page":"718","DOI":"10.4049\/jimmunol.1700183","article-title":"The bile acid receptor GPBAR1 regulates the M1\/M2 phenotype of intestinal macrophages and activation of GPBAR1 rescues mice from murine colitis","volume":"199","author":"Biagioli","year":"2017","journal-title":"J Immunol"},{"key":"10.1016\/j.plipres.2021.101094_bb0975","doi-asserted-by":"crossref","first-page":"9435","DOI":"10.1074\/jbc.M209706200","article-title":"A G protein-coupled receptor responsive to bile acids","volume":"278","author":"Kawamata","year":"2003","journal-title":"J Biol Chem"},{"key":"10.1016\/j.plipres.2021.101094_bb0980","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1016\/j.bbrc.2008.04.171","article-title":"Expression and function of the bile acid receptor TGR5 in Kupffer cells","volume":"372","author":"Keitel","year":"2008","journal-title":"Biochem Biophys Res Commun"},{"key":"10.1016\/j.plipres.2021.101094_bb0985","doi-asserted-by":"crossref","first-page":"759","DOI":"10.1038\/nature03988","article-title":"A SUMOylation-dependent pathway mediates transrepression of inflammatory response genes by PPAR-gamma","volume":"437","author":"Pascual","year":"2005","journal-title":"Nature"},{"key":"10.1016\/j.plipres.2021.101094_bb0990","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1007\/164_2019_236","article-title":"Bile acid-activated receptors: a review on FXR and other nuclear receptors","volume":"256","author":"Shin","year":"2019","journal-title":"Handb Exp Pharmacol"},{"key":"10.1016\/j.plipres.2021.101094_bb0995","doi-asserted-by":"crossref","first-page":"1497","DOI":"10.1053\/j.gastro.2004.08.001","article-title":"The nuclear receptor SHP mediates inhibition of hepatic stellate cells by FXR and protects against liver fibrosis","volume":"127","author":"Fiorucci","year":"2004","journal-title":"Gastroenterology"},{"key":"10.1016\/j.plipres.2021.101094_bb1000","doi-asserted-by":"crossref","first-page":"2294","DOI":"10.1158\/1535-7163.MCT-16-0153","article-title":"A novel small molecule activator of nuclear receptor SHP inhibits HCC cell migration via suppressing Ccl2","volume":"15","author":"Yang","year":"2016","journal-title":"Mol Cancer Ther"},{"key":"10.1016\/j.plipres.2021.101094_bb1005","doi-asserted-by":"crossref","first-page":"20559","DOI":"10.1038\/srep20559","article-title":"Bcl2 is a critical regulator of bile acid homeostasis by dictating Shp and lncRNA H19 function","volume":"6","author":"Zhang","year":"2016","journal-title":"Sci Rep"},{"key":"10.1016\/j.plipres.2021.101094_bb1010","first-page":"851","article-title":"Activation of bile salt nuclear receptor FXR is repressed by pro-inflammatory cytokines activating NF-\u03baB signaling in the intestine","volume":"2011","author":"Gadaleta","year":"1812","journal-title":"Biochim Biophys Acta"},{"key":"10.1016\/j.plipres.2021.101094_bb1015","first-page":"166","article-title":"Splenic dendritic cell involvement in FXR-mediated amelioration of DSS colitis","volume":"2016","author":"Massafra","year":"1862","journal-title":"Biochim Biophys Acta"},{"key":"10.1016\/j.plipres.2021.101094_bb1020","doi-asserted-by":"crossref","first-page":"802","DOI":"10.1016\/j.immuni.2016.09.008","article-title":"Bile acids control inflammation and metabolic disorder through inhibition of NLRP3 inflammasome","volume":"45","author":"Guo","year":"2016","journal-title":"Immunity"},{"key":"10.1016\/j.plipres.2021.101094_bb1025","doi-asserted-by":"crossref","first-page":"944","DOI":"10.1016\/j.immuni.2016.10.009","article-title":"Bile acids control inflammation and metabolic disorder through inhibition of NLRP3 inflammasome","volume":"45","author":"Guo","year":"2016","journal-title":"Immunity"},{"key":"10.1016\/j.plipres.2021.101094_bb1030","doi-asserted-by":"crossref","first-page":"83951","DOI":"10.18632\/oncotarget.13796","article-title":"Chenodeoxycholic acid activates NLRP3 inflammasome and contributes to cholestatic liver fibrosis","volume":"7","author":"Gong","year":"2016","journal-title":"Oncotarget"},{"key":"10.1016\/j.plipres.2021.101094_bb1035","doi-asserted-by":"crossref","first-page":"856","DOI":"10.1016\/j.cmet.2017.03.007","article-title":"Farnesoid X receptor regulation of the NLRP3 inflammasome underlies cholestasis-associated sepsis","volume":"25","author":"Hao","year":"2017","journal-title":"Cell Metab"},{"key":"10.1016\/j.plipres.2021.101094_bb1040","first-page":"112","article-title":"Hepatoprotection by the farnesoid X receptor agonist GW4064 in rat models of intra- and extrahepatic cholestasis","volume":"2003","author":"Liu","year":"1678","journal-title":"J Clin Invest"},{"key":"10.1016\/j.plipres.2021.101094_bb1045","doi-asserted-by":"crossref","first-page":"6115","DOI":"10.1038\/ncomms7115","article-title":"Small heterodimer partner interacts with NLRP3 and negatively regulates activation of the NLRP3 inflammasome","volume":"6","author":"Yang","year":"2015","journal-title":"Nat Commun"},{"key":"10.1016\/j.plipres.2021.101094_bb1050","doi-asserted-by":"crossref","first-page":"742","DOI":"10.1038\/ni.2064","article-title":"The orphan nuclear receptor SHP acts as a negative regulator in inflammatory signaling triggered by Toll-like receptors","volume":"12","author":"Yuk","year":"2011","journal-title":"Nat Immunol"},{"key":"10.1016\/j.plipres.2021.101094_bb1055","doi-asserted-by":"crossref","first-page":"584","DOI":"10.1124\/jpet.105.084905","article-title":"A farnesoid x receptor-small heterodimer partner regulatory cascade modulates tissue metalloproteinase inhibitor-1 and matrix metalloprotease expression in hepatic stellate cells and promotes resolution of liver fibrosis","volume":"314","author":"Fiorucci","year":"2005","journal-title":"J Pharmacol Exp Ther"},{"key":"10.1016\/j.plipres.2021.101094_bb1060","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1124\/jpet.105.085597","article-title":"Cross-talk between farnesoid-X-receptor (FXR) and peroxisome proliferator-activated receptor gamma contributes to the antifibrotic activity of FXR ligands in rodent models of liver cirrhosis","volume":"315","author":"Fiorucci","year":"2005","journal-title":"J Pharmacol Exp Ther"},{"key":"10.1016\/j.plipres.2021.101094_bb1065","doi-asserted-by":"crossref","first-page":"604","DOI":"10.1124\/jpet.104.079665","article-title":"Protective effects of 6-ethyl chenodeoxycholic acid, a farnesoid X receptor ligand, in estrogen-induced cholestasis","volume":"313","author":"Fiorucci","year":"2005","journal-title":"J Pharmacol Exp Ther"},{"key":"10.1016\/j.plipres.2021.101094_bb1070","doi-asserted-by":"crossref","first-page":"631","DOI":"10.1056\/NEJMoa1509840","article-title":"A placebo-controlled trial of obeticholic acid in primary biliary cholangitis","volume":"375","author":"Nevens","year":"2016","journal-title":"N Engl J Med"},{"key":"10.1016\/j.plipres.2021.101094_bb1075","doi-asserted-by":"crossref","first-page":"1109","DOI":"10.4155\/fmc.15.54","article-title":"Steroidal scaffolds as FXR and GPBAR1 ligands: from chemistry to therapeutical application","volume":"7","author":"Sepe","year":"2015","journal-title":"Future Med Chem"},{"key":"10.1016\/j.plipres.2021.101094_bb1080","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1007\/164_2019_228","article-title":"Pharmacologic modulation of bile acid-FXR-FGF15\/FGF19 pathway for the treatment of nonalcoholic steatohepatitis","volume":"256","author":"Schumacher","year":"2019","journal-title":"Handb Exp Pharmacol"},{"key":"10.1016\/j.plipres.2021.101094_bb1085","doi-asserted-by":"crossref","first-page":"1877","DOI":"10.1111\/liv.13477","article-title":"Treatment of primary biliary cholangitis ursodeoxycholic acid non-responders: a systematic review","volume":"37","author":"Suraweera","year":"2017","journal-title":"Liver Int"},{"key":"10.1016\/j.plipres.2021.101094_bb1090","doi-asserted-by":"crossref","first-page":"751","DOI":"10.1053\/j.gastro.2014.12.005","article-title":"Efficacy of obeticholic acid in patients with primary biliary cirrhosis and inadequate response to ursodeoxycholic acid","volume":"148","author":"Hirschfield","year":"2015","journal-title":"Gastroenterology"},{"key":"10.1016\/j.plipres.2021.101094_bb1095","doi-asserted-by":"crossref","DOI":"10.1111\/apt.16023","article-title":"Review article: pathophysiology and management of primary biliary cholangitis","author":"Leung","year":"2020","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1016\/j.plipres.2021.101094_bb1100","doi-asserted-by":"crossref","first-page":"445","DOI":"10.1016\/S2468-1253(19)30094-9","article-title":"Long-term efficacy and safety of obeticholic acid for patients with primary biliary cholangitis: 3-year results of an international open-label extension study","volume":"4","author":"Trauner","year":"2019","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"10.1016\/j.plipres.2021.101094_bb1105","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1016\/j.jhep.2020.02.033","article-title":"A randomized, placebo-controlled, phase II study of obeticholic acid for primary sclerosing cholangitis","volume":"73","author":"Kowdley","year":"2020","journal-title":"J Hepatol"},{"key":"10.1016\/j.plipres.2021.101094_bb1110","doi-asserted-by":"crossref","first-page":"328","DOI":"10.1111\/cts.12421","article-title":"Modeling and experimental studies of obeticholic acid exposure and the impact of cirrhosis stage","volume":"9","author":"Edwards","year":"2016","journal-title":"Clin Transl Sci"},{"key":"10.1016\/j.plipres.2021.101094_bb1115","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1053\/j.gastro.2018.04.032","article-title":"Mechanisms of MAFG dysregulation in cholestatic liver injury and development of liver cancer","volume":"155","author":"Liu","year":"2018","journal-title":"Gastroenterology"},{"key":"10.1016\/j.plipres.2021.101094_bb1120","doi-asserted-by":"crossref","first-page":"771","DOI":"10.1194\/jlr.M001602","article-title":"FXR activation reverses insulin resistance and lipid abnormalities and protects against liver steatosis in Zucker (fa\/fa) obese rats","volume":"51","author":"Cipriani","year":"2010","journal-title":"J Lipid Res"},{"key":"10.1016\/j.plipres.2021.101094_bb1125","doi-asserted-by":"crossref","first-page":"956","DOI":"10.1016\/S0140-6736(14)61933-4","article-title":"Farnesoid X nuclear receptor ligand obeticholic acid for non-cirrhotic, non-alcoholic steatohepatitis (FLINT): a multicentre, randomised, placebo-controlled trial","volume":"385","author":"Neuschwander-Tetri","year":"2015","journal-title":"Lancet"},{"key":"10.1016\/j.plipres.2021.101094_bb1130","doi-asserted-by":"crossref","first-page":"2184","DOI":"10.1016\/S0140-6736(19)33041-7","article-title":"Obeticholic acid for the treatment of non-alcoholic steatohepatitis: interim analysis from a multicentre, randomised, placebo-controlled phase 3 trial","volume":"394","author":"Younossi","year":"2019","journal-title":"Lancet"},{"key":"10.1016\/j.plipres.2021.101094_bb1135","doi-asserted-by":"crossref","first-page":"986","DOI":"10.1016\/j.jhep.2019.06.011","article-title":"Obeticholic acid may increase the risk of gallstone formation in susceptible patients","volume":"71","author":"Al-Dury","year":"2019","journal-title":"J Hepatol"},{"key":"10.1016\/j.plipres.2021.101094_bb1140","doi-asserted-by":"crossref","first-page":"645","DOI":"10.1111\/apt.14492","article-title":"Clinical and metabolic effects associated with weight changes and obeticholic acid in non-alcoholic steatohepatitis","volume":"47","author":"Hameed","year":"2018","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1016\/j.plipres.2021.101094_bb1145","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1016\/j.jhep.2019.10.006","article-title":"Impact of obeticholic acid on the lipoprotein profile in patients with non-alcoholic steatohepatitis","volume":"72","author":"Siddiqui","year":"2020","journal-title":"J Hepatol"},{"key":"10.1016\/j.plipres.2021.101094_bb1150","first-page":"39","article-title":"CONTROL: A randomized phase 2 study of obeticholic acid and atorvastatin on lipoproteins in nonalcoholic steatohepatitis patients","volume":"2082-2093","author":"Pockros","year":"2019","journal-title":"Liver Int"},{"key":"10.1016\/j.plipres.2021.101094_bb1155","doi-asserted-by":"crossref","first-page":"574","DOI":"10.1053\/j.gastro.2013.05.042","article-title":"Efficacy and safety of the farnesoid X receptor agonist obeticholic acid in patients with type 2 diabetes and nonalcoholic fatty liver disease","volume":"145","author":"Mudaliar","year":"2013","journal-title":"Gastroenterology"},{"key":"10.1016\/j.plipres.2021.101094_bb1160","doi-asserted-by":"crossref","first-page":"788","DOI":"10.1002\/hep.30509","article-title":"The nonsteroidal farnesoid X receptor agonist cilofexor (GS-9674) improves markers of cholestasis and liver injury in patients with primary sclerosing cholangitis","volume":"70","author":"Trauner","year":"2019","journal-title":"Hepatology"},{"key":"10.1016\/j.plipres.2021.101094_bb1165","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1002\/hep.31205","article-title":"Cilofexor, a nonsteroidal FXR agonist, in patients with noncirrhotic NASH: a phase 2 randomized controlled trial","volume":"72","author":"Patel","year":"2020","journal-title":"Hepatology"},{"key":"10.1016\/j.plipres.2021.101094_bb1170","doi-asserted-by":"crossref","DOI":"10.1103\/PhysRevLett.112.091303","article-title":"First results from the LUX dark matter experiment at the Sanford underground research facility","volume":"112","author":"Akerib","year":"2014","journal-title":"Phys Rev Lett"},{"key":"10.1016\/j.plipres.2021.101094_bb1175","doi-asserted-by":"crossref","first-page":"105889","DOI":"10.1016\/j.cct.2019.105889","article-title":"A randomized, double-blind, multicenter, phase 2b study to evaluate the safety and efficacy of a combination of tropifexor and cenicriviroc in patients with nonalcoholic steatohepatitis and liver fibrosis: Study design of the TANDEM trial","volume":"88","author":"Pedrosa","year":"2020","journal-title":"Contemp Clin Trials"},{"key":"10.1016\/j.plipres.2021.101094_bb1180","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1080\/13543776.2018.1459569","article-title":"Farnesoid X receptor modulators 2014-present: a patent review","volume":"28","author":"Sepe","year":"2018","journal-title":"Expert Opin Ther Pat"},{"key":"10.1016\/j.plipres.2021.101094_bb1185","doi-asserted-by":"crossref","first-page":"3868","DOI":"10.1021\/acs.jmedchem.9b01621","article-title":"Nidufexor (LMB763), a novel FXR modulator for the treatment of nonalcoholic steatohepatitis","volume":"63","author":"Chianelli","year":"2020","journal-title":"J Med Chem"},{"key":"10.1016\/j.plipres.2021.101094_bb1190","doi-asserted-by":"crossref","first-page":"6120","DOI":"10.1074\/jbc.C500457200","article-title":"Regulation of fibroblast growth factor-23 signaling by klotho","volume":"281","author":"Kurosu","year":"2006","journal-title":"J Biol Chem"},{"key":"10.1016\/j.plipres.2021.101094_bb1195","doi-asserted-by":"crossref","first-page":"7432","DOI":"10.1073\/pnas.0701600104","article-title":"BetaKlotho is required for metabolic activity of fibroblast growth factor 21","volume":"104","author":"Ogawa","year":"2007","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.plipres.2021.101094_bb1200","doi-asserted-by":"crossref","first-page":"770","DOI":"10.1038\/nature05315","article-title":"Klotho converts canonical FGF receptor into a specific receptor for FGF23","volume":"444","author":"Urakawa","year":"2006","journal-title":"Nature"},{"key":"10.1016\/j.plipres.2021.101094_bb1205","doi-asserted-by":"crossref","first-page":"29069","DOI":"10.1074\/jbc.C700130200","article-title":"Co-receptor requirements for fibroblast growth factor-19 signaling","volume":"282","author":"Wu","year":"2007","journal-title":"J Biol Chem"},{"key":"10.1016\/j.plipres.2021.101094_bb1210","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1146\/annurev-physiol-030212-183727","article-title":"Fibroblast growth factor 23 and Klotho: physiology and pathophysiology of an endocrine network of mineral metabolism","volume":"75","author":"Hu","year":"2013","journal-title":"Annu Rev Physiol"},{"key":"10.1016\/j.plipres.2021.101094_bb1215","doi-asserted-by":"crossref","first-page":"26687","DOI":"10.1074\/jbc.M704165200","article-title":"Tissue-specific expression of betaKlotho and fibroblast growth factor (FGF) receptor isoforms determines metabolic activity of FGF19 and FGF21","volume":"282","author":"Kurosu","year":"2007","journal-title":"J Biol Chem"},{"key":"10.1016\/j.plipres.2021.101094_bb1220","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0049977","article-title":"FGF21 requires \u03b2klotho to act in vivo","volume":"7","author":"Adams","year":"2012","journal-title":"PLoS One"},{"key":"10.1016\/j.plipres.2021.101094_bb1225","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1016\/j.cmet.2012.08.002","article-title":"\u03b2Klotho is required for fibroblast growth factor 21 effects on growth and metabolism","volume":"16","author":"Ding","year":"2012","journal-title":"Cell Metab"},{"key":"10.1016\/j.plipres.2021.101094_bb1230","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1002\/jcp.21357","article-title":"FGF-21\/FGF-21 receptor interaction and activation is determined by betaKlotho","volume":"215","author":"Kharitonenkov","year":"2008","journal-title":"J Cell Physiol"},{"key":"10.1016\/j.plipres.2021.101094_bb1235","doi-asserted-by":"crossref","first-page":"2050","DOI":"10.1210\/me.2010-0142","article-title":"Research resource: Comprehensive expression atlas of the fibroblast growth factor system in adult mouse","volume":"24","author":"Fon Tacer","year":"2010","journal-title":"Mol Endocrinol"},{"key":"10.1016\/j.plipres.2021.101094_bb1240","doi-asserted-by":"crossref","first-page":"729","DOI":"10.1006\/cyto.1999.0485","article-title":"FGF-19, a novel fibroblast growth factor with unique specificity for FGFR4","volume":"11","author":"Xie","year":"1999","journal-title":"Cytokine"},{"key":"10.1016\/j.plipres.2021.101094_bb1245","doi-asserted-by":"crossref","first-page":"4230","DOI":"10.3748\/wjg.v13.i31.4230","article-title":"Lithocholic acid induction of the FGF19 promoter in intestinal cells is mediated by PXR","volume":"13","author":"Wistuba","year":"2007","journal-title":"World J Gastroenterol"},{"key":"10.1016\/j.plipres.2021.101094_bb1250","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1038\/nrm3312","article-title":"Transcriptional integration of metabolism by the nuclear sterol-activated receptors LXR and FXR","volume":"13","author":"Calkin","year":"2012","journal-title":"Nat Rev Mol Cell Biol"},{"key":"10.1016\/j.plipres.2021.101094_bb1255","doi-asserted-by":"crossref","first-page":"1581","DOI":"10.1101\/gad.1083503","article-title":"Definition of a novel growth factor-dependent signal cascade for the suppression of bile acid biosynthesis","volume":"17","author":"Holt","year":"2003","journal-title":"Genes Dev"},{"key":"10.1016\/j.plipres.2021.101094_bb1260","doi-asserted-by":"crossref","first-page":"2664","DOI":"10.1194\/jlr.M700330-JLR200","article-title":"Differential regulation of bile acid homeostasis by the farnesoid X receptor in liver and intestine","volume":"48","author":"Kim","year":"2007","journal-title":"J Lipid Res"},{"key":"10.1016\/j.plipres.2021.101094_bb1265","doi-asserted-by":"crossref","first-page":"429","DOI":"10.1194\/jlr.M078279","article-title":"Diet1, bile acid diarrhea, and FGF15\/19: mouse model and human genetic variants","volume":"59","author":"Lee","year":"2018","journal-title":"J Lipid Res"},{"key":"10.1016\/j.plipres.2021.101094_bb1270","doi-asserted-by":"crossref","first-page":"916","DOI":"10.1016\/j.cmet.2013.04.007","article-title":"Diet1 functions in the FGF15\/19 enterohepatic signaling axis to modulate bile acid and lipid levels","volume":"17","author":"Vergnes","year":"2013","journal-title":"Cell Metab"},{"key":"10.1016\/j.plipres.2021.101094_bb1275","doi-asserted-by":"crossref","first-page":"1253","DOI":"10.1038\/nm1501","article-title":"Identification of a hormonal basis for gallbladder filling","volume":"12","author":"Choi","year":"2006","journal-title":"Nat Med"},{"key":"10.1016\/j.plipres.2021.101094_bb1280","doi-asserted-by":"crossref","first-page":"14379","DOI":"10.1073\/pnas.0907812106","article-title":"Selective activation of FGFR4 by an FGF19 variant does not improve glucose metabolism in ob\/ob mice","volume":"106","author":"Wu","year":"2009","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.plipres.2021.101094_bb1285","doi-asserted-by":"crossref","first-page":"530","DOI":"10.1111\/j.1365-2796.2006.01731.x","article-title":"Circulating intestinal fibroblast growth factor 19 has a pronounced diurnal variation and modulates hepatic bile acid synthesis in man","volume":"260","author":"Lund\u00e5sen","year":"2006","journal-title":"J Intern Med"},{"key":"10.1016\/j.plipres.2021.101094_bb1290","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1038\/ajg.2015.424","article-title":"Characterizing factors associated with differences in FGF19 blood levels and synthesis in patients with primary bile acid diarrhea","volume":"111","author":"Johnston","year":"2016","journal-title":"Am J Gastroenterol"},{"key":"10.1016\/j.plipres.2021.101094_bb1295","doi-asserted-by":"crossref","first-page":"G440","DOI":"10.1152\/ajpgi.00322.2009","article-title":"The hepatic response to FGF19 is impaired in patients with nonalcoholic fatty liver disease and insulin resistance","volume":"298","author":"Schreuder","year":"2010","journal-title":"Am J Physiol Gastrointest Liver Physiol"},{"key":"10.1016\/j.plipres.2021.101094_bb1300","first-page":"390","article-title":"Fibroblast growth factor-19 levels in type 2 diabetic patients with metabolic syndrome","volume":"41","author":"Barutcuoglu","year":"2011","journal-title":"Ann Clin Lab Sci"},{"key":"10.1016\/j.plipres.2021.101094_bb1305","doi-asserted-by":"crossref","first-page":"861","DOI":"10.1016\/j.clnu.2016.04.027","article-title":"FGF19 and FGF21 serum concentrations in human obesity and type 2 diabetes behave differently after diet- or surgically-induced weight loss","volume":"36","author":"G\u00f3mez-Ambrosi","year":"2017","journal-title":"Clin Nutr"},{"key":"10.1016\/j.plipres.2021.101094_bb1310","doi-asserted-by":"crossref","first-page":"371","DOI":"10.1016\/j.soard.2012.01.021","article-title":"Effect of bypassing the proximal gut on gut hormones involved with glycemic control and weight loss","volume":"8","author":"Pournaras","year":"2012","journal-title":"Surg Obes Relat Dis"},{"key":"10.1016\/j.plipres.2021.101094_bb1315","doi-asserted-by":"crossref","first-page":"1741","DOI":"10.1210\/endo.143.5.8850","article-title":"Transgenic mice expressing human fibroblast growth factor-19 display increased metabolic rate and decreased adiposity","volume":"143","author":"Tomlinson","year":"2002","journal-title":"Endocrinology"},{"key":"10.1016\/j.plipres.2021.101094_bb1320","doi-asserted-by":"crossref","first-page":"2594","DOI":"10.1210\/en.2003-1671","article-title":"Fibroblast growth factor 19 increases metabolic rate and reverses dietary and leptin-deficient diabetes","volume":"145","author":"Fu","year":"2004","journal-title":"Endocrinology"},{"key":"10.1016\/j.plipres.2021.101094_bb1325","doi-asserted-by":"crossref","first-page":"1885","DOI":"10.1248\/bpb.34.1885","article-title":"Fibroblast growth factor 19 treatment ameliorates disruption of hepatic lipid metabolism in farnesoid X receptor (Fxr)-null mice","volume":"34","author":"Miyata","year":"2011","journal-title":"Biol Pharm Bull"},{"key":"10.1016\/j.plipres.2021.101094_bb1330","doi-asserted-by":"crossref","first-page":"10023","DOI":"10.1074\/jbc.M808818200","article-title":"Fibroblast growth factor-19, a novel factor that inhibits hepatic fatty acid synthesis","volume":"284","author":"Bhatnagar","year":"2009","journal-title":"J Biol Chem"},{"key":"10.1016\/j.plipres.2021.101094_bb1335","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1194\/jlr.M027094","article-title":"Dual actions of fibroblast growth factor 19 on lipid metabolism","volume":"54","author":"Wu","year":"2013","journal-title":"J Lipid Res"},{"key":"10.1016\/j.plipres.2021.101094_bb1340","doi-asserted-by":"crossref","first-page":"1712","DOI":"10.1002\/hep.30951","article-title":"Fibroblast growth factor 19-mediated up-regulation of SYR-related high-mobility group box 18 promotes hepatocellular carcinoma metastasis by transactivating fibroblast growth factor receptor 4 and fms-related tyrosine kinase 4","volume":"71","author":"Chen","year":"2020","journal-title":"Hepatology"},{"key":"10.1016\/j.plipres.2021.101094_bb1345","doi-asserted-by":"crossref","first-page":"15433","DOI":"10.1038\/ncomms15433","article-title":"Non-cell-autonomous activation of IL-6\/STAT3 signaling mediates FGF19-driven hepatocarcinogenesis","volume":"8","author":"Zhou","year":"2017","journal-title":"Nat Commun"},{"key":"10.1016\/j.plipres.2021.101094_bb1350","doi-asserted-by":"crossref","first-page":"57633","DOI":"10.18632\/oncotarget.9328","article-title":"Fibroblast growth factor receptor 4 (FGFR4) and fibroblast growth factor 19 (FGF19) autocrine enhance breast cancer cells survival","volume":"7","author":"Tiong","year":"2016","journal-title":"Oncotarget"},{"key":"10.1016\/j.plipres.2021.101094_bb1355","doi-asserted-by":"crossref","first-page":"2394","DOI":"10.1038\/s41388-018-0591-7","article-title":"FGF19 amplification reveals an oncogenic dependency upon autocrine FGF19\/FGFR4 signaling in head and neck squamous cell carcinoma","volume":"38","author":"Gao","year":"2019","journal-title":"Oncogene"},{"key":"10.1016\/j.plipres.2021.101094_bb1360","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1016\/j.ccr.2011.01.040","article-title":"Identification of a therapeutic strategy targeting amplified FGF19 in liver cancer by Oncogenomic screening","volume":"19","author":"Sawey","year":"2011","journal-title":"Cancer Cell"},{"key":"10.1016\/j.plipres.2021.101094_bb1365","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0052711","article-title":"Regulation of amphiregulin gene expression by \u03b2-catenin signaling in human hepatocellular carcinoma cells: a novel crosstalk between FGF19 and the EGFR system","volume":"7","author":"Latasa","year":"2012","journal-title":"PLoS One"},{"key":"10.1016\/j.plipres.2021.101094_bb1370","doi-asserted-by":"crossref","first-page":"27277","DOI":"10.1074\/jbc.M704244200","article-title":"Liver-specific activities of FGF19 require Klotho beta","volume":"282","author":"Lin","year":"2007","journal-title":"J Biol Chem"},{"key":"10.1016\/j.plipres.2021.101094_bb1375","doi-asserted-by":"crossref","first-page":"33304","DOI":"10.1074\/jbc.M803319200","article-title":"C-terminal tail of FGF19 determines its specificity toward Klotho co-receptors","volume":"283","author":"Wu","year":"2008","journal-title":"J Biol Chem"},{"key":"10.1016\/j.plipres.2021.101094_bb1380","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0036713","article-title":"Targeting FGFR4 inhibits hepatocellular carcinoma in preclinical mouse models","volume":"7","author":"French","year":"2012","journal-title":"PLoS One"},{"key":"10.1016\/j.plipres.2021.101094_bb1385","doi-asserted-by":"crossref","first-page":"3306","DOI":"10.1158\/0008-5472.CAN-14-0208","article-title":"Separating tumorigenicity from bile acid regulatory activity for endocrine hormone FGF19","volume":"74","author":"Zhou","year":"2014","journal-title":"Cancer Res"},{"key":"10.1016\/j.plipres.2021.101094_bb1390","unstructured":"Harrison, S.; Guy, C.; Bashir, M.; Frias, J.P.; Alkhouri, N.; Baum, S.; Taub, R.; Moylan, C.; Bansal, B.; Neuschwander-Tetri, B., et al. In a placebo-controlled 36-week phase 2 trial, treatment with Mgl-3196 compared to placebo results in significant reductions in hepatic fat (MRI-PDFF), liver enzymes, fibrosis biomarkers, atherogenic lipids, and improvement in nash on serial liver biopsy. In Proceedings of Annual Meeting of the American-Association-for-the-Study-of-Liver-Diseases (AASLD)\/Liver Meeting, San Francisco, CA; pp. 9A-10A."},{"key":"10.1016\/j.plipres.2021.101094_bb1395","doi-asserted-by":"crossref","first-page":"725","DOI":"10.1038\/s41395-018-0042-7","article-title":"Effects of NGM282, an FGF19 variant, on colonic transit and bowel function in functional constipation: a randomized phase 2 trial","volume":"113","author":"Oduyebo","year":"2018","journal-title":"Am J Gastroenterol"},{"key":"10.1016\/j.plipres.2021.101094_bb1400","doi-asserted-by":"crossref","first-page":"4057","DOI":"10.2337\/db14-0595","article-title":"Circulating FGF21 is liver derived and enhances glucose uptake during refeeding and overfeeding","volume":"63","author":"Markan","year":"2014","journal-title":"Diabetes"},{"key":"10.1016\/j.plipres.2021.101094_bb1405","doi-asserted-by":"crossref","first-page":"654","DOI":"10.1038\/s41574-020-0386-0","article-title":"The therapeutic potential of FGF21 in metabolic diseases: from bench to clinic","volume":"16","author":"Geng","year":"2020","journal-title":"Nat Rev Endocrinol"},{"key":"10.1016\/j.plipres.2021.101094_bb1410","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1016\/j.cmet.2007.05.003","article-title":"Endocrine regulation of the fasting response by PPARalpha-mediated induction of fibroblast growth factor 21","volume":"5","author":"Inagaki","year":"2007","journal-title":"Cell Metab"},{"key":"10.1016\/j.plipres.2021.101094_bb1415","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1016\/j.cmet.2008.05.006","article-title":"Inhibition of growth hormone signaling by the fasting-induced hormone FGF21","volume":"8","author":"Inagaki","year":"2008","journal-title":"Cell Metab"},{"key":"10.1016\/j.plipres.2021.101094_bb1420","doi-asserted-by":"crossref","first-page":"10853","DOI":"10.1073\/pnas.0904187106","article-title":"FGF21 induces PGC-1alpha and regulates carbohydrate and fatty acid metabolism during the adaptive starvation response","volume":"106","author":"Potthoff","year":"2009","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.plipres.2021.101094_bb1425","doi-asserted-by":"crossref","first-page":"4064","DOI":"10.2337\/db14-0541","article-title":"FGF21 maintains glucose homeostasis by mediating the cross talk between liver and brain during prolonged fasting","volume":"63","author":"Liang","year":"2014","journal-title":"Diabetes"},{"key":"10.1016\/j.plipres.2021.101094_bb1430","doi-asserted-by":"crossref","first-page":"779","DOI":"10.1016\/j.cmet.2013.04.005","article-title":"Adiponectin mediates the metabolic effects of FGF21 on glucose homeostasis and insulin sensitivity in mice","volume":"17","author":"Lin","year":"2013","journal-title":"Cell Metab"},{"key":"10.1016\/j.plipres.2021.101094_bb1435","doi-asserted-by":"crossref","first-page":"458","DOI":"10.1172\/JCI80223","article-title":"Interplay between FGF21 and insulin action in the liver regulates metabolism","volume":"125","author":"Emanuelli","year":"2015","journal-title":"J Clin Invest"},{"key":"10.1016\/j.plipres.2021.101094_bb1440","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1016\/j.cmet.2016.02.001","article-title":"A long-acting FGF21 molecule, PF-05231023, decreases body weight and improves lipid profile in non-human primates and type 2 diabetic subjects","volume":"23","author":"Talukdar","year":"2016","journal-title":"Cell Metab"},{"key":"10.1016\/j.plipres.2021.101094_bb1445","doi-asserted-by":"crossref","first-page":"1015","DOI":"10.1016\/j.molmet.2016.07.003","article-title":"Fibroblast activation protein (FAP) as a novel metabolic target","volume":"5","author":"S\u00e1nchez-Garrido","year":"2016","journal-title":"Mol Metab"},{"key":"10.1016\/j.plipres.2021.101094_bb1450","doi-asserted-by":"crossref","first-page":"695","DOI":"10.1002\/hep.21458","article-title":"The G-protein coupled bile salt receptor TGR5 is expressed in liver sinusoidal endothelial cells","volume":"45","author":"Keitel","year":"2007","journal-title":"Hepatology"},{"key":"10.1016\/j.plipres.2021.101094_bb1455","doi-asserted-by":"crossref","first-page":"5620","DOI":"10.3748\/wjg.14.5620","article-title":"Endocrine and paracrine role of bile acids","volume":"14","author":"Keitel","year":"2008","journal-title":"World J Gastroenterol"},{"key":"10.1016\/j.plipres.2021.101094_bb1460","doi-asserted-by":"crossref","first-page":"861","DOI":"10.1002\/hep.23032","article-title":"The membrane-bound bile acid receptor TGR5 is localized in the epithelium of human gallbladders","volume":"50","author":"Keitel","year":"2009","journal-title":"Hepatology"},{"key":"10.1016\/j.plipres.2021.101094_bb1465","doi-asserted-by":"crossref","first-page":"13320","DOI":"10.1038\/srep13320","article-title":"Bile acids induce hepatic differentiation of mesenchymal stem cells","volume":"5","author":"Sawitza","year":"2015","journal-title":"Sci Rep"},{"key":"10.1016\/j.plipres.2021.101094_bb1470","doi-asserted-by":"crossref","DOI":"10.3390\/nu12072124","article-title":"Compound 18 improves glucose tolerance in a hepatocyte TGR5-dependent manner in mice","volume":"12","author":"Holter","year":"2020","journal-title":"Nutrients"},{"key":"10.1016\/j.plipres.2021.101094_bb1475","doi-asserted-by":"crossref","first-page":"1794","DOI":"10.1002\/glia.21049","article-title":"The bile acid receptor TGR5 (Gpbar-1) acts as a neurosteroid receptor in brain","volume":"58","author":"Keitel","year":"2010","journal-title":"Glia"},{"key":"10.1016\/j.plipres.2021.101094_bb1480","doi-asserted-by":"crossref","first-page":"1417","DOI":"10.1053\/j.gastro.2014.08.042","article-title":"The bile acid receptor TGR5 activates the TRPA1 channel to induce itch in mice","volume":"147","author":"Lieu","year":"2014","journal-title":"Gastroenterology"},{"key":"10.1016\/j.plipres.2021.101094_bb1485","doi-asserted-by":"crossref","first-page":"814","DOI":"10.1111\/j.1365-2982.2010.01487.x","article-title":"Expression and function of the bile acid receptor GpBAR1 (TGR5) in the murine enteric nervous system","volume":"22","author":"Poole","year":"2010","journal-title":"Neurogastroenterol Motil"},{"key":"10.1016\/j.plipres.2021.101094_bb1490","doi-asserted-by":"crossref","first-page":"1513","DOI":"10.1172\/JCI64551","article-title":"The TGR5 receptor mediates bile acid-induced itch and analgesia","volume":"123","author":"Alemi","year":"2013","journal-title":"J Clin Invest"},{"key":"10.1016\/j.plipres.2021.101094_bb1495","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1053\/j.gastro.2012.09.055","article-title":"The receptor TGR5 mediates the prokinetic actions of intestinal bile acids and is required for normal defecation in mice","volume":"144","author":"Alemi","year":"2013","journal-title":"Gastroenterology"},{"key":"10.1016\/j.plipres.2021.101094_bb1500","doi-asserted-by":"crossref","first-page":"G1013","DOI":"10.1152\/ajpgi.00383.2012","article-title":"Ciliary subcellular localization of TGR5 determines the cholangiocyte functional response to bile acid signaling","volume":"304","author":"Masyuk","year":"2013","journal-title":"Am J Physiol Gastrointest Liver Physiol"},{"key":"10.1016\/j.plipres.2021.101094_bb1505","doi-asserted-by":"crossref","first-page":"170","DOI":"10.1136\/gut.2009.188375","article-title":"Role of a novel bile acid receptor TGR5 in the development of oesophageal adenocarcinoma","volume":"59","author":"Hong","year":"2010","journal-title":"Gut"},{"key":"10.1016\/j.plipres.2021.101094_bb1510","doi-asserted-by":"crossref","first-page":"569","DOI":"10.1002\/cmdc.201200474","article-title":"2-Phenoxy-nicotinamides are potent agonists at the bile acid receptor GPBAR1 (TGR5)","volume":"8","author":"Martin","year":"2013","journal-title":"ChemMedChem"},{"key":"10.1016\/j.plipres.2021.101094_bb1515","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1007\/164_2019_230","article-title":"Bile acid-activated receptors: GPBAR1 (TGR5) and other G protein-coupled receptors","volume":"256","author":"Keitel","year":"2019","journal-title":"Handb Exp Pharmacol"},{"key":"10.1016\/j.plipres.2021.101094_bb1520","doi-asserted-by":"crossref","first-page":"7958","DOI":"10.1021\/jm901390p","article-title":"Discovery of 6alpha-ethyl-23(S)-methylcholic acid (S-EMCA, INT-777) as a potent and selective agonist for the TGR5 receptor, a novel target for diabesity","volume":"52","author":"Pellicciari","year":"2009","journal-title":"J Med Chem"},{"key":"10.1016\/j.plipres.2021.101094_bb1525","doi-asserted-by":"crossref","first-page":"5424","DOI":"10.1172\/JCI76289","article-title":"TGR5 reduces macrophage migration through mTOR-induced C\/EBPbeta differential translation","volume":"124","author":"Perino","year":"2014","journal-title":"J Clin Invest"},{"key":"10.1016\/j.plipres.2021.101094_bb1530","doi-asserted-by":"crossref","first-page":"5424","DOI":"10.1172\/JCI76289","article-title":"TGR5 reduces macrophage migration through mTOR-induced C\/EBP\u03b2 differential translation","volume":"124","author":"Perino","year":"2014","journal-title":"J Clin Invest"},{"key":"10.1016\/j.plipres.2021.101094_bb1535","doi-asserted-by":"crossref","first-page":"747","DOI":"10.1016\/j.cmet.2011.11.006","article-title":"TGR5 activation inhibits atherosclerosis by reducing macrophage inflammation and lipid loading","volume":"14","author":"Pols","year":"2011","journal-title":"Cell Metab"},{"key":"10.1016\/j.plipres.2021.101094_bb1540","doi-asserted-by":"crossref","first-page":"4185","DOI":"10.1021\/acs.jmedchem.6b01873","article-title":"Topical intestinal aminoimidazole agonists of G-protein-coupled bile acid receptor 1 promote glucagon like peptide-1 secretion and improve glucose tolerance","volume":"60","author":"Lasalle","year":"2017","journal-title":"J Med Chem"},{"key":"10.1016\/j.plipres.2021.101094_bb1545","doi-asserted-by":"crossref","first-page":"10475","DOI":"10.1021\/jm301071h","article-title":"Design, synthesis, and antidiabetic activity of 4-phenoxynicotinamide and 4-phenoxypyrimidine-5-carboxamide derivatives as potent and orally efficacious TGR5 agonists","volume":"55","author":"Duan","year":"2012","journal-title":"J Med Chem"},{"key":"10.1016\/j.plipres.2021.101094_bb1550","doi-asserted-by":"crossref","first-page":"3315","DOI":"10.1021\/jm500829b","article-title":"Discovery of intestinal targeted TGR5 agonists for the treatment of type 2 diabetes","volume":"58","author":"Duan","year":"2015","journal-title":"J Med Chem"},{"key":"10.1016\/j.plipres.2021.101094_bb1555","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.ejmech.2014.05.031","article-title":"4-Benzofuranyloxynicotinamide derivatives are novel potent and orally available TGR5 agonists","volume":"82","author":"Zou","year":"2014","journal-title":"Eur J Med Chem"},{"key":"10.1016\/j.plipres.2021.101094_bb1560","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1111\/dom.12636","article-title":"Therapeutic potential of takeda-G-protein-receptor-5 (TGR5) agonists. Hope or hype?","volume":"18","author":"Hodge","year":"2016","journal-title":"Diabetes Obes Metab"},{"key":"10.1016\/j.plipres.2021.101094_bb1565","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1002\/cpdd.34","article-title":"Safety, pharmacokinetics, and pharmacodynamic effects of a selective TGR5 agonist, SB-756050, in type 2 diabetes","volume":"2","author":"Hodge","year":"2013","journal-title":"Clin Pharmacol Drug Dev"},{"key":"10.1016\/j.plipres.2021.101094_bb1570","doi-asserted-by":"crossref","first-page":"484","DOI":"10.1038\/nature04330","article-title":"Bile acids induce energy expenditure by promoting intracellular thyroid hormone activation","volume":"439","author":"Watanabe","year":"2006","journal-title":"Nature"},{"key":"10.1016\/j.plipres.2021.101094_bb1575","doi-asserted-by":"crossref","first-page":"386","DOI":"10.1016\/j.bbrc.2005.01.139","article-title":"Bile acids promote glucagon-like peptide-1 secretion through TGR5 in a murine enteroendocrine cell line STC-1","volume":"329","author":"Katsuma","year":"2005","journal-title":"Biochem Biophys Res Commun"},{"key":"10.1016\/j.plipres.2021.101094_bb1580","doi-asserted-by":"crossref","first-page":"1671","DOI":"10.1038\/oby.2009.102","article-title":"Serum bile acids are higher in humans with prior gastric bypass: potential contribution to improved glucose and lipid metabolism","volume":"17","author":"Patti","year":"2009","journal-title":"Obesity (Silver Spring)"},{"key":"10.1016\/j.plipres.2021.101094_bb1585","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1084\/jem.20171965","article-title":"Bile acids in glucose metabolism in health and disease","volume":"215","author":"Shapiro","year":"2018","journal-title":"J Exp Med"},{"key":"10.1016\/j.plipres.2021.101094_bb1590","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1677\/JOE-10-0009","article-title":"Gender-dependent effect of Gpbar1 genetic deletion on the metabolic profiles of diet-induced obese mice","volume":"205","author":"Vassileva","year":"2010","journal-title":"J Endocrinol"},{"key":"10.1016\/j.plipres.2021.101094_bb1595","doi-asserted-by":"crossref","first-page":"600","DOI":"10.1016\/j.bbrc.2012.09.104","article-title":"Activation of transmembrane bile acid receptor TGR5 stimulates insulin secretion in pancreatic \u03b2 cells","volume":"427","author":"Kumar","year":"2012","journal-title":"Biochem Biophys Res Commun"},{"key":"10.1016\/j.plipres.2021.101094_bb1600","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0136873","article-title":"Novel small molecule agonist of TGR5 possesses anti-diabetic effects but causes gallbladder filling in mice","volume":"10","author":"Briere","year":"2015","journal-title":"PLoS One"},{"key":"10.1016\/j.plipres.2021.101094_bb1605","doi-asserted-by":"crossref","first-page":"806","DOI":"10.1038\/ijo.2015.1","article-title":"Temporal changes in bile acid levels and 12\u03b1-hydroxylation after Roux-en-Y gastric bypass surgery in type 2 diabetes","volume":"39","author":"Dutia","year":"2015","journal-title":"Int J Obes"},{"key":"10.1016\/j.plipres.2021.101094_bb1610","doi-asserted-by":"crossref","first-page":"957","DOI":"10.1007\/s11695-015-1834-0","article-title":"FGF 19 and bile acids increase following roux-en-Y gastric bypass but not after medical management in patients with type 2 diabetes","volume":"26","author":"Sachdev","year":"2016","journal-title":"Obes Surg"},{"key":"10.1016\/j.plipres.2021.101094_bb1615","doi-asserted-by":"crossref","first-page":"G527","DOI":"10.1152\/ajpgi.00388.2012","article-title":"Activation of G protein-coupled bile acid receptor, TGR5, induces smooth muscle relaxation via both Epac- and PKA-mediated inhibition of RhoA\/Rho kinase pathway","volume":"304","author":"Rajagopal","year":"2013","journal-title":"Am J Physiol Gastrointest Liver Physiol"},{"key":"10.1016\/j.plipres.2021.101094_bb1620","doi-asserted-by":"crossref","first-page":"G863","DOI":"10.1152\/ajpgi.00380.2014","article-title":"Upregulation of bile acid receptor TGR5 and nNOS in gastric myenteric plexus is responsible for delayed gastric emptying after chronic high-fat feeding in rats","volume":"308","author":"Zhou","year":"2015","journal-title":"Am J Physiol Gastrointest Liver Physiol"},{"key":"10.1016\/j.plipres.2021.101094_bb1625","doi-asserted-by":"crossref","first-page":"61021","DOI":"10.18632\/oncotarget.10477","article-title":"The bile acid receptor GPBAR1 (TGR5) is expressed in human gastric cancers and promotes epithelial-mesenchymal transition in gastric cancer cell lines","volume":"7","author":"Carino","year":"2016","journal-title":"Oncotarget"},{"key":"10.1016\/j.plipres.2021.101094_bb1630","doi-asserted-by":"crossref","first-page":"G508","DOI":"10.1152\/ajpgi.00178.2014","article-title":"Genetic variation in GPBAR1 predisposes to quantitative changes in colonic transit and bile acid excretion","volume":"307","author":"Camilleri","year":"2014","journal-title":"Am J Physiol Gastrointest Liver Physiol"},{"key":"10.1016\/j.plipres.2021.101094_bb1635","first-page":"C777","article-title":"Chenodeoxycholic acid requires activation of EGFR, EPAC, and Ca2+ to stimulate CFTR-dependent Cl- secretion in human colonic T84 cells","volume":"311","author":"Domingue","year":"2016","journal-title":"Am J Phys Cell Phys"},{"key":"10.1016\/j.plipres.2021.101094_bb1640","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0025637","article-title":"The bile acid receptor GPBAR-1 (TGR5) modulates integrity of intestinal barrier and immune response to experimental colitis","volume":"6","author":"Cipriani","year":"2011","journal-title":"PLoS One"},{"key":"10.1016\/j.plipres.2021.101094_bb1645","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1111\/j.1365-2567.2012.03554.x","article-title":"Bile acids induce monocyte differentiation toward interleukin-12 hypo-producing dendritic cells via a TGR5-dependent pathway","volume":"136","author":"Ichikawa","year":"2012","journal-title":"Immunology"},{"key":"10.1016\/j.plipres.2021.101094_bb1650","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1042\/BJ20060537","article-title":"Targeted deletion of Gpbar1 protects mice from cholesterol gallstone formation","volume":"398","author":"Vassileva","year":"2006","journal-title":"Biochem J"},{"key":"10.1016\/j.plipres.2021.101094_bb1655","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1055\/s-0038-1669940","article-title":"Role of TGR5 (GPBAR1) in liver disease","volume":"38","author":"Keitel","year":"2018","journal-title":"Semin Liver Dis"},{"key":"10.1016\/j.plipres.2021.101094_bb1660","doi-asserted-by":"crossref","first-page":"847","DOI":"10.1016\/j.tips.2015.08.002","article-title":"TGR5 and immunometabolism: insights from physiology and pharmacology","volume":"36","author":"Perino","year":"2015","journal-title":"Trends Pharmacol Sci"},{"key":"10.1016\/j.plipres.2021.101094_bb1665","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1111\/imr.12579","article-title":"Interactions between bile salts, gut microbiota, and hepatic innate immunity","volume":"279","author":"Schubert","year":"2017","journal-title":"Immunol Rev"},{"key":"10.1016\/j.plipres.2021.101094_bb1670","doi-asserted-by":"crossref","first-page":"1253","DOI":"10.1189\/jlb.0812396","article-title":"Bile acids PKA-dependently induce a switch of the IL-10\/IL-12 ratio and reduce proinflammatory capability of human macrophages","volume":"94","author":"Haselow","year":"2013","journal-title":"J Leukoc Biol"},{"key":"10.1016\/j.plipres.2021.101094_bb1675","article-title":"Bile acid signaling in inflammatory bowel diseases","author":"Fiorucci","year":"2020","journal-title":"Dig Dis Sci"},{"key":"10.1016\/j.plipres.2021.101094_bb1680","doi-asserted-by":"crossref","first-page":"11761","DOI":"10.1074\/jbc.M112.446575","article-title":"Bile acid receptor activation modulates hepatic monocyte activity and improves nonalcoholic fatty liver disease","volume":"288","author":"McMahan","year":"2013","journal-title":"J Biol Chem"},{"key":"10.1016\/j.plipres.2021.101094_bb1685","doi-asserted-by":"crossref","first-page":"42801","DOI":"10.1038\/srep42801","article-title":"BAR502, a dual FXR and GPBAR1 agonist, promotes browning of white adipose tissue and reverses liver steatosis and fibrosis","volume":"7","author":"Carino","year":"2017","journal-title":"Sci Rep"},{"key":"10.1016\/j.plipres.2021.101094_bb1690","doi-asserted-by":"crossref","first-page":"13689","DOI":"10.1038\/s41598-017-13102-y","article-title":"Gpbar1 agonism promotes a Pgc-1\u03b1-dependent browning of white adipose tissue and energy expenditure and reverses diet-induced steatohepatitis in mice","volume":"7","author":"Carino","year":"2017","journal-title":"Sci Rep"},{"key":"10.1016\/j.plipres.2021.101094_bb1695","doi-asserted-by":"crossref","first-page":"10343","DOI":"10.1021\/jm501052c","article-title":"G-protein-coupled bile acid receptor 1 (GPBAR1, TGR5) agonists reduce the production of proinflammatory cytokines and stabilize the alternative macrophage phenotype","volume":"57","author":"H\u00f6genauer","year":"2014","journal-title":"J Med Chem"},{"key":"10.1016\/j.plipres.2021.101094_bb1700","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1111\/imm.12045","article-title":"TGR5 signalling inhibits the production of pro-inflammatory cytokines by in vitro differentiated inflammatory and intestinal macrophages in Crohn's disease","volume":"139","author":"Yoneno","year":"2013","journal-title":"Immunology"},{"key":"10.1016\/j.plipres.2021.101094_bb1705","doi-asserted-by":"crossref","first-page":"447","DOI":"10.1016\/j.jcmgh.2019.06.003","article-title":"GPBAR1 functions as gatekeeper for liver NKT cells and provides counterregulatory signals in mouse models of immune-mediated hepatitis","volume":"8","author":"Biagioli","year":"2019","journal-title":"Cell Mol Gastroenterol Hepatol"},{"key":"10.1016\/j.plipres.2021.101094_bb1710","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0141082","article-title":"Reversal of endothelial dysfunction by GPBAR1 agonism in portal hypertension involves a AKT\/FOXOA1 dependent regulation of H2S generation and endothelin-1","volume":"10","author":"Renga","year":"2015","journal-title":"PLoS One"},{"key":"10.1016\/j.plipres.2021.101094_bb1715","first-page":"33","article-title":"Bile acid receptor TGR5 agonism induces NO production and reduces monocyte adhesion in vascular endothelial cells","volume":"2013","author":"Kida","year":"1663","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"10.1016\/j.plipres.2021.101094_bb1720","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1124\/jpet.113.209288","article-title":"Stimulation of G protein-coupled bile acid receptor enhances vascular endothelial barrier function via activation of protein kinase A and Rac1","volume":"348","author":"Kida","year":"2014","journal-title":"J Pharmacol Exp Ther"},{"key":"10.1016\/j.plipres.2021.101094_bb1725","doi-asserted-by":"crossref","first-page":"85","DOI":"10.2174\/187152811794776286","article-title":"Hydrogen sulfide generation in mammals: the molecular biology of cystathionine-\u03b2- synthase (CBS) and cystathionine-\u03b3-lyase (CSE)","volume":"10","author":"Renga","year":"2011","journal-title":"Inflamm Allergy Drug Targets"},{"key":"10.1016\/j.plipres.2021.101094_bb1730","doi-asserted-by":"crossref","first-page":"879","DOI":"10.1111\/jcmm.12077","article-title":"Crosstalk between hydrogen sulfide and nitric oxide in endothelial cells","volume":"17","author":"Altaany","year":"2013","journal-title":"J Cell Mol Med"},{"key":"10.1016\/j.plipres.2021.101094_bb1735","doi-asserted-by":"crossref","first-page":"2809","DOI":"10.1096\/fj.201801373RR","article-title":"Agonism for the bile acid receptor GPBAR1 reverses liver and vascular damage in a mouse model of steatohepatitis","volume":"33","author":"Carino","year":"2019","journal-title":"FASEB J"},{"key":"10.1016\/j.plipres.2021.101094_bb1740","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0129866","article-title":"Impaired itching perception in murine models of cholestasis is supported by dysregulation of GPBAR1 signaling","volume":"10","author":"Cipriani","year":"2015","journal-title":"PLoS One"},{"key":"10.1016\/j.plipres.2021.101094_bb1745","doi-asserted-by":"crossref","DOI":"10.7554\/eLife.44116","article-title":"Identification of a bilirubin receptor that may mediate a component of cholestatic itch","volume":"8","author":"Meixiong","year":"2019","journal-title":"Elife"},{"key":"10.1016\/j.plipres.2021.101094_bb1750","doi-asserted-by":"crossref","first-page":"1163","DOI":"10.1016\/j.immuni.2019.03.013","article-title":"Activation of mast-cell-expressed mas-related G-protein-coupled receptors drives non-histaminergic itch","volume":"50","author":"Meixiong","year":"2019","journal-title":"Immunity"},{"key":"10.1016\/j.plipres.2021.101094_bb1755","doi-asserted-by":"crossref","DOI":"10.7554\/eLife.48431","article-title":"MRGPRX4 is a bile acid receptor for human cholestatic itch","volume":"8","author":"Yu","year":"2019","journal-title":"Elife"},{"key":"10.1016\/j.plipres.2021.101094_bb1760","doi-asserted-by":"crossref","first-page":"10525","DOI":"10.1073\/pnas.1903316116","article-title":"MRGPRX4 is a G protein-coupled receptor activated by bile acids that may contribute to cholestatic pruritus","volume":"116","author":"Meixiong","year":"2019","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.plipres.2021.101094_bb1765","doi-asserted-by":"crossref","first-page":"4893","DOI":"10.1021\/bi002836k","article-title":"Enzymes of sphingolipid metabolism: from modular to integrative signaling","volume":"40","author":"Hannun","year":"2001","journal-title":"Biochemistry"},{"key":"10.1016\/j.plipres.2021.101094_bb1770","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1016\/j.plipres.2016.03.001","article-title":"Sphingosine 1-phosphate and sphingosine kinases in health and disease: recent advances","volume":"62","author":"Pyne","year":"2016","journal-title":"Prog Lipid Res"},{"key":"10.1016\/j.plipres.2021.101094_bb1775","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1002\/hep.24681","article-title":"Conjugated bile acids activate the sphingosine-1-phosphate receptor 2 in primary rodent hepatocytes","volume":"55","author":"Studer","year":"2012","journal-title":"Hepatology"},{"key":"10.1016\/j.plipres.2021.101094_bb1780","doi-asserted-by":"crossref","first-page":"2234","DOI":"10.1194\/jlr.M004929","article-title":"Bile acids regulate hepatic gluconeogenic genes and farnesoid X receptor via G(alpha)i-protein-coupled receptors and the AKT pathway","volume":"51","author":"Cao","year":"2010","journal-title":"J Lipid Res"},{"key":"10.1016\/j.plipres.2021.101094_bb1785","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1016\/j.livres.2019.02.003","article-title":"Sphingosine-1-phosphate signaling and the gut-liver axis in liver diseases","volume":"3","author":"Kwong","year":"2019","journal-title":"Liver Res"},{"key":"10.1016\/j.plipres.2021.101094_bb1790","first-page":"65","article-title":"The role of sphingosine 1-phosphate receptor 2 in bile-acid-induced cholangiocyte proliferation and cholestasis-induced liver injury in mice","volume":"2017","author":"Wang","year":"2005","journal-title":"Hepatology"},{"key":"10.1016\/j.plipres.2021.101094_bb1795","doi-asserted-by":"crossref","first-page":"1149","DOI":"10.3389\/fimmu.2020.01149","article-title":"Macrophage sphingosine 1-phosphate receptor 2 blockade attenuates liver inflammation and fibrogenesis triggered by NLRP3 inflammasome","volume":"11","author":"Hou","year":"2020","journal-title":"Front Immunol"},{"key":"10.1016\/j.plipres.2021.101094_bb1800","doi-asserted-by":"crossref","first-page":"637","DOI":"10.1002\/emmm.201100172","article-title":"Adipogenesis and insulin sensitivity in obesity are regulated by retinoid-related orphan receptor gamma","volume":"3","author":"Meissburger","year":"2011","journal-title":"EMBO Mol Med"},{"key":"10.1016\/j.plipres.2021.101094_bb1805","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1084\/jem.20100052","article-title":"Microbiota-induced tertiary lymphoid tissues aggravate inflammatory disease in the absence of RORgamma t and LTi cells","volume":"208","author":"Lochner","year":"2011","journal-title":"J Exp Med"},{"key":"10.1016\/j.plipres.2021.101094_bb1810","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1038\/mi.2016.86","article-title":"ROR\u03b3t, a multitask nuclear receptor at mucosal surfaces","volume":"10","author":"Eberl","year":"2017","journal-title":"Mucosal Immunol"},{"key":"10.1016\/j.plipres.2021.101094_bb1815","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1111\/j.1600-065X.2011.01071.x","article-title":"Development and evolution of ROR\u03b3t+ cells in a microbe's world","volume":"245","author":"Eberl","year":"2012","journal-title":"Immunol Rev"},{"key":"10.1016\/j.plipres.2021.101094_bb1820","doi-asserted-by":"crossref","first-page":"97","DOI":"10.4049\/jimmunol.1501175","article-title":"Progression from nonalcoholic fatty liver to nonalcoholic steatohepatitis is marked by a higher frequency of Th17 cells in the liver and an increased Th17\/resting regulatory T cell ratio in peripheral blood and in the liver","volume":"196","author":"Rau","year":"2016","journal-title":"J Immunol"},{"key":"10.1016\/j.plipres.2021.101094_bb1825","doi-asserted-by":"crossref","DOI":"10.1621\/nrs.07003","article-title":"Retinoid-related orphan receptors (RORs): critical roles in development, immunity, circadian rhythm, and cellular metabolism","volume":"7","author":"Jetten","year":"2009","journal-title":"Nucl Recept Signal"},{"key":"10.1016\/j.plipres.2021.101094_bb1830","doi-asserted-by":"crossref","first-page":"1743","DOI":"10.1210\/me.2007-0566","article-title":"Adopting new orphans into the family of metabolic regulators","volume":"22","author":"Hummasti","year":"2008","journal-title":"Mol Endocrinol"},{"key":"10.1016\/j.plipres.2021.101094_bb1835","doi-asserted-by":"crossref","first-page":"485","DOI":"10.1146\/annurev.immunol.021908.132710","article-title":"IL-17 and Th17 cells","volume":"27","author":"Korn","year":"2009","journal-title":"Annu Rev Immunol"},{"key":"10.1016\/j.plipres.2021.101094_bb1840","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1034\/j.1600-065X.2003.00074.x","article-title":"The role of the nuclear hormone receptor RORgammat in the development of lymph nodes and Peyer's patches","volume":"195","author":"Eberl","year":"2003","journal-title":"Immunol Rev"},{"key":"10.1016\/j.plipres.2021.101094_bb1845","doi-asserted-by":"crossref","first-page":"320","DOI":"10.1038\/ni.2002","article-title":"ROR\u03b3t+ innate lymphoid cells regulate intestinal homeostasis by integrating negative signals from the symbiotic microbiota","volume":"12","author":"Sawa","year":"2011","journal-title":"Nat Immunol"},{"key":"10.1016\/j.plipres.2021.101094_bb1850","doi-asserted-by":"crossref","first-page":"1249288","DOI":"10.1126\/science.1249288","article-title":"Microbiota-dependent crosstalk between macrophages and ILC3 promotes intestinal homeostasis","volume":"343","author":"Mortha","year":"2014","journal-title":"Science"},{"key":"10.1016\/j.plipres.2021.101094_bb1855","doi-asserted-by":"crossref","first-page":"698","DOI":"10.1038\/nm.3892","article-title":"Innate lymphoid cells in the initiation, regulation and resolution of inflammation","volume":"21","author":"Sonnenberg","year":"2015","journal-title":"Nat Med"},{"key":"10.1016\/j.plipres.2021.101094_bb1860","first-page":"3","article-title":"Orphan nuclear receptor modulators","volume":"2003","author":"Mohan","year":"1637","journal-title":"Curr Top Med Chem"},{"key":"10.1016\/j.plipres.2021.101094_bb1865","doi-asserted-by":"crossref","first-page":"923","DOI":"10.1210\/me.2009-0507","article-title":"Structural basis for hydroxycholesterols as natural ligands of orphan nuclear receptor RORgamma","volume":"24","author":"Jin","year":"2010","journal-title":"Mol Endocrinol"},{"key":"10.1016\/j.plipres.2021.101094_bb1870","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1038\/nm.4046","article-title":"Transient inhibition of ROR-\u03b3t therapeutically limits intestinal inflammation by reducing TH17 cells and preserving group 3 innate lymphoid cells","volume":"22","author":"Withers","year":"2016","journal-title":"Nat Med"},{"key":"10.1016\/j.plipres.2021.101094_bb1875","doi-asserted-by":"crossref","first-page":"2307","DOI":"10.3389\/fimmu.2018.02307","article-title":"An ROR\u03b3t oral inhibitor modulates IL-17 responses in peripheral blood and intestinal mucosa of crohn's disease patients","volume":"9","author":"Bassolas-Molina","year":"2018","journal-title":"Front Immunol"}],"container-title":["Progress in Lipid Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0163782721000102?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0163782721000102?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,27]],"date-time":"2025-09-27T22:44:10Z","timestamp":1759013050000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0163782721000102"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,4]]},"references-count":375,"alternative-id":["S0163782721000102"],"URL":"https:\/\/doi.org\/10.1016\/j.plipres.2021.101094","relation":{},"ISSN":["0163-7827"],"issn-type":[{"value":"0163-7827","type":"print"}],"subject":[],"published":{"date-parts":[[2021,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Bile acids and their receptors in metabolic disorders","name":"articletitle","label":"Article Title"},{"value":"Progress in Lipid Research","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.plipres.2021.101094","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"101094"}}